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THESIS ABSTRACT 
Background and Aim 
Diabetes is a serious global public health issue. Diabetes-related complications are a 
significant source of morbidity, premature mortality and a major contributor to 
health care costs. Understanding the epidemiology of diabetes and related 
complications is essential to identify public health priorities for planning and tackling 
the problem. This includes identifying possible contributing factors to prevent and 
delay the onset of diabetes related complications. Blindness due to diabetic 
retinopathy is a serious complication of diabetes which is potentially preventable by 
adequate risk factor control, early detection and timely treatment. In 2013, a national 
diabetic retinopathy screening programme (Diabetic Retinascreen) was introduced 
in Ireland. Reliable data are needed to evaluate and assess the implementation of 
this service and its potential for future impact. The aim of this thesis was to estimate 
the public health burden of diabetes in Ireland including time trends and 
determinants of complications and to investigate the implementation of a public 
health intervention for people with diabetes.   
Methods 
Data from four nationally representative studies, identified by a systematic review, 
were used to explore trends in diagnosed diabetes prevalence between 1998 and 
2015. Cross-sectional analysis of data from the first wave of The Irish Longitudinal 
Study on Ageing (TILDA) (2009–2011) was carried out to estimate the prevalence of 
diagnosed type 2 diabetes and its related complications in adults aged 50 years and 
over; determinants of macro-and microvascular complications were identified. 
Trends of visual impairment and blindness due to diabetic retinopathy in adults aged 
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18–69 years over a decade were described using data from the National Council for 
the Blind of Ireland, (2004–2013) and changes in rates were explored. The final study, 
a realist evaluation with an iterative mixed-methods design, was carried out to 
investigate the implementation and uptake of Diabetic Retinascreen.  
Results 
In adults aged 18 years and over, the national prevalence of doctor diagnosed 
diabetes significantly increased from 2.1% in 1998 to 5.2% in 2015. The prevalence 
of diabetes complications varied depending on study population and methodology 
used. 
In TILDA, diagnosed type 2 diabetes prevalence was 8.4%. Among participants with 
diagnosed type 2 diabetes, the overall prevalence of macrovascular complications 
was 15.1% and the overall prevalence of microvascular complications was 26.0%. 
Older age, being male, a history of smoking, a lower level of physical activity, and a 
diagnosis of high cholesterol were independent predictors of macrovascular 
complications. Diabetes diagnosis of 10 or more years, a history of smoking, and a 
diagnosis of hypertension were associated with an increased risk of microvascular 
complications. Older age, third-level education, and a high level of physical activity 
were protective factors. 
Over a decade, the incidence of visual impairment due to diabetic retinopathy 
increased in both the total population and the population with diagnosed diabetes. 
In contrast, the incidence of blindness due to diabetic retinopathy in the total 
population did not significantly change during the study period. The annual incidence 
in the population with diabetes varied between years (31.9 per 100,000 [95% CI 21.6-
17 
 
45.7] in 2004 to 14.9 per 100,000 [95% CI 8.2-25.1] in 2013) however, there was no 
evidence of a linear trend.  
 
The evaluation of the initial implementation of the Diabetic Retinascreen programme 
indicated that over a 14 month period, a total of 63% of people with diabetes 
attended screening. The refined theory of how the programme worked was that 
people were more likely to consent when they perceived that the service was a 
relevant to them and had a relative advantage over existing services. This reaction 
was trigged in a context where people heard about Diabetic Retinascreen from a 
trusted and familiar person and were dissatisfied with existing services. Furthermore 
they perceived their own risk of diabetic retinopathy to be high and understood the 
purpose of screening. Once consented, people were more likely to attend their 
screening appointment with Diabetic Retinascreen because personal and service 
flexibility made access seem easy. 
Conclusions: Research in this thesis is an important contribution to our 
understanding of the public health burden of diabetes in Ireland. In the absence of a 
national diabetes register, findings provide robust estimates on the trends in the 
incidence and prevalence of diagnosed diabetes and its complications among adults 
aged 18 years and over. Findings have provided a key source of information to 
facilitate diabetes program planning and to inform policy decisions, including 
resource allocation. In Ireland, the population at risk is increasing each year therefore 
maximising uptake of diabetic retinopathy screening must be a priority. 
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1.1 Introduction 
Diabetes is a serious global public health issue which has been described as the most 
challenging health problem in the 21st century (1, 2). Cases of diabetes have 
progressively increased worldwide (3); driven primarily by rising levels of obesity and 
ageing populations (2, 4). Diabetes places a substantial burden on the individual, 
society and the economy. Much of this burden is attributable to the macrovascular 
(myocardial infarction, congestive cardiac failure, cerebrovascular accident, transient 
ischaemic attack) and microvascular (diabetic retinopathy, diabetic neuropathy and 
diabetic nephropathy) complications of diabetes (5). As the prevalence of diabetes 
rises, diabetes related complications represent a growing global public health and 
health service challenge (6). 
In response to these challenges, the National Clinical Programme for Diabetes (NCPD) 
was established in 2010 to ‘ascertain and reduce the prevalence of diabetes in Ireland 
and to reduce the burden of diabetes on both affected individuals and the State by 
reducing the morbidity and mortality associated with diabetes’ achieved through the 
reorganization of existing services and the introduction of new services and supports 
for people with diabetes (7). Dedicated work streams were established for the 
implementation of a national diabetic retinopathy screening programme (Diabetic 
Retinascreen), a national model of care for the screening and treatment of diabetic 
foot disease, and a national model of integrated care for the management of 
diabetes across primary, secondary and tertiary care settings.  
Good-quality epidemiological data on the incidence and prevalence of diabetes and 
related complications are important to support the planning and implementation of 
20 
 
public health policies and programmes, and to determine research priorities (8-12). 
Within-country data are needed to quantify the population at risk and to monitor 
trends in the health impacts of diabetes. These data are vital for planning health 
services and for monitoring the effectiveness of interventions aimed to reduce the 
burden of diabetes over time (8-12).  
Ireland does not have a national diabetes register or universal data-capture system 
to assess trends of diabetes and related complications. The lack of a unique patient 
health identifier is a unique limitation in Ireland preventing linkage of individual 
patient data from various healthcare sources. The Euro Diabetes Index (2014) stated 
that there was a lack of reliable data to monitor diabetes related complications in 
Ireland (13).  
Trends in the incidence of lower-leg amputations in people with diabetes over a five 
year period were recently reported (14); however, contemporary data on trends of 
visual impairment due to diabetic retinopathy are lacking. In 2010, the World Health 
Organisation (WHO) highlighted the importance of within-country data on visual 
impairment to facilitate global efforts aimed at monitoring and eliminating avoidable 
blindness (15). The introduction of a national retinopathy screening programme 
(Diabetic Retinascreen) in 2013 provides an opportunity for the first time to monitor 
rates of blindness. However, uptake has been highlighted as a concern nationally and 
internationally. Additionally, the early implementation stage of Diabetic 
Retinascreen highlighted programme uptake as a concern. Hence, there is an urgent 
need to explore this further to provide formative information for the future roll out 
of the programme. 
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1.2 Aim 
 
The overarching aim of this thesis was: 
To estimate the public health burden of diabetes in Ireland including time trends and 
determinants of complications and to evaluate the implementation of a public health 
intervention to prevent and delay the development of a complication for people with 
diabetes.   
1.3 Objectives 
Specifically, the objectives were:  
1. To systematically identify and summarise studies describing the prevalence 
of diabetes and the most common macrovascular and microvascular 
complications among adults aged 18 years and over in Ireland between 1998 
and 2014 and to describe trends in diagnosed diabetes prevalence between 
1998 and 2015. 
 
2. To estimate the prevalence of diagnosed type 2 diabetes among adults aged 
50 years and over and to determine the prevalence of macrovascular and 
microvascular and complications in those with diagnosed type 2 diabetes.  
 
3. To identify the determinants of macrovascular and microvascular 
complications among adults aged 50 years and over with diagnosed type 2 
diabetes. 
 
22 
 
4. To describe trends in the incidence of visual impairment and blindness due to 
diabetic retinopathy over a ten-year period (2004–2013) and to explore 
whether these rates changed over time.  
 
5. To carry out a theory-driven evaluation of the initial uptake of Diabetic 
Retinascreen to understand how the programme was working, for whom and 
in what circumstances.  
1.4 Research setting  
1.4.1 Describing the public health burden of diabetes and related complications 
among adults age 18 years and over in Ireland 
The following existing national datasets were obtained for secondary analysis in this 
research (Chapters 3-6): the National Survey of Health and Lifestyles in Ireland (SLÁN) 
(16-18), The Irish Longitudinal Study on Ageing (TILDA) (19) and the National Council 
for the Blind in Ireland (NCBI) (20).  
1.4.2 Understanding the uptake of the national retinopathy screening 
programme: a realist evaluation  
This study is original research using primary data collection and analysis. Data were 
collected as part of a wider on-going evaluation of the NCPD which is adopting a 
realist approach. The overall evaluation is examining the implementation of three 
on-going work streams of the NCPD: the national model of foot care for people with 
diabetes; the national model of integrated care for diabetes and the national diabetic 
retinopathy screening programme. The study protocol has been published in 
Implementation Science (21) (Appendix 1).  
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1.5 Thesis outline 
This thesis contains eight chapters, five of which are studies addressing the aims and 
objectives outlined above. Figure 1 illustrates the five studies and the corresponding 
chapters. 
Chapter 2 provides a brief introduction to the extent of the problem of diabetes and 
related complications. Recommendations to address this problem, including 
retinopathy screening programmes, are reviewed and factors that determine 
screening attendance are explored. 
A systematic review was undertaken which describes trends in the prevalence of 
doctor diagnosed diabetes among adults in the Republic of Ireland between 1998 
and 2015 (Chapter 3). The rationale for carrying out this systematic review was to 
highlight current gaps in existing knowledge; findings from this paper informed the 
research for this thesis. These data had not been systematically collated prior to this 
thesis being undertaken.  
Chapter 4 investigates the prevalence of diagnosed type 2 diabetes and four 
macrovascular complications (myocardial infarction, congestive cardiac failure, 
cerebrovascular accident, transient ischaemic attack) and five microvascular 
complications (leg ulcer, proteinuria, diabetic neuropathy, diabetic retinopathy, 
diabetic nephropathy) among a nationally representative sample of adults aged 50 
years and over in Ireland. Individual level determinants of these complications are 
explored in Chapter 5. Individual factors assessed are age, gender, educational 
attainment, smoking, physical activity, and previous diagnosis of hypertension and 
high cholesterol.  
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Chapter 6 investigates rates of visual impairment and blindness due to diabetic 
retinopathy in the total population and the population with diabetes in the Republic 
of Ireland. Data obtained from the NCBI were used as the numerator and data on the 
population at risk were based on prevalence figures calculated in Chapter 3.  
Uptake of Diabetic Retinascreen is examined in Chapter 7. Factors which influence 
the decision to participate (or not) in the national diabetic retinopathy screening 
programme are explored among people with diabetes who were eligible to use this 
service over a 14-month period.  
Chapter 8 provides an overall discussion of the main findings, the strengths and 
limitations of this thesis and makes suggestions for future research. 
This PhD project is presented in the format of a collated thesis, comprised of a series 
of publications in peer-reviewed academic journals. Chapters 3, 4, 5 and 6 have been 
published. Chapter 7 is being prepared for publication at the time of printing of the 
thesis.  
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Figure 1. Overview of thesis including aims and objectives 
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1.6 Conceptual Framework 
The conceptual framework for the research in this thesis is based the ‘measurement 
iterative loop’ which was developed by Tugwell et al., 1985 (12) (Figure 2).  
 
Figure 2. Measurement iterative loop 
The framework consists of an iterative cycle of five stages for assembling health 
information and evaluating public health interventions. Each stage underpins each 
chapter of this thesis (Table 1) and place the individual studies in context. Using the 
framework allows for the systematic identification of areas in which further research 
is needed. The iterative loop or similar approaches have been applied in a variety of 
areas such as the management of the diabetic foot (22), technology assessment (23), 
cancer control (24), policy development (25) and paediatric emergency medicine 
(26). 
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Table 1. Steps in the measurement iterative loop 
Step          Questions Thesis chapter 
1: Statement of the public 
health issue 
 What is diabetes? 
 Why is diabetes a public health issue? 
 
 Chapter 2 
2: Describe the public 
health burden of disease 
and explore risk factors 
 What is the public health burden of 
diabetes and related complications in 
Ireland?  
 What are the trends of diabetes and 
related complications in Ireland? 
- Have these trends changed over time? 
 What are the risk factors for diabetes 
complications? 
 
 Chapters 3-6 
3: Recommendations to 
reduce disease burden 
 What works to reduce the public health 
burden of visual impairment due to 
diabetic retinopathy?  
 
 Chapter 2  
4: Implementation of 
recommendation 
 How was uptake of the national diabetic 
retinopathy screening programme 
expected to work? 
 
 Chapter 7 
5: Evaluation of public 
health programme 
 How is uptake of the national diabetic 
retinopathy screening programme working 
in practice?  
 Chapter 7 
 
1.7 Author’s contribution 
I was the lead author of all of the papers contained in this thesis. This involved the 
formulation of the research question for each chapter, conducting literature 
searching, data collection, data management, data analysis and drafting of each 
manuscript. A summary of my role in each Chapter is provided in Appendix 2. 
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2. BACKGROUND  
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This chapter provides a brief overview of diabetes and related complications. First, 
diabetes as an important public health issue is considered. Second, the extent of the 
problem globally is described. Third, health consequences of diabetes and 
determinants of complications are outlined. Next, to place Chapters 6 and 7 in 
context, the focus then moves to one serious microvascular complication, diabetes 
retinopathy, providing a summary of international rates and considers diabetic 
retinopathy screening programmes as an effective public health intervention. Finally, 
factors which determine attendance at such programmes are described. 
2.1 What is diabetes? 
Diabetes is a group of chronic metabolic conditions, which are associated with 
hyperglycaemia, either because the pancreas does not produce enough insulin, or 
because the body cannot effectively use the insulin that is produced, or both (27). In 
general, the type of diabetes is categorised into four groups: 
1. Type 1 diabetes is characterised by a complete lack of insulin production and 
accounts for 5% to 10% of all cases;  
2. Type 2 diabetes is characterized by insulin resistance or relative insulin 
deficiency. Type 2 diabetes is the most common form and accounts for 
approximately 90% of all cases;  
3. Gestational diabetes is hyperglycaemia that is first recognized during 
pregnancy; 
4. Other types of diabetes such as maturity-onset diabetes of youth or latent 
autoimmune diabetes in adults are caused by specific genetic conditions or 
from surgery, medications, infections, pancreatic disease, or other illnesses 
and accounts for 1% to 5% of all diagnosed cases (27) . 
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2.2 Diabetes as an important public health issue 
Diabetes is a significant cause of premature mortality and morbidity (5). Over the 
past number of years, the global public health burden of diabetes has continued to 
rise (5, 28, 29). Type 2 diabetes is the main driver of the epidemic, accounting for 
approximately 90% of all cases (2). The increasing burden of diabetes is driven 
primarily by rising levels of obesity and an ageing population (2, 30). 
Between 1990 and 2013, mortality rates for diabetes increased by 9.0% (29). Since 
1990, disability due to diabetes has also grown substantially, with particularly large 
increases among people aged 15–49 years (28). The Global Burden of Disease Study 
reported that diabetes was the ninth leading cause of mortality in 2013 (29) and the 
11th largest cause of disability adjusted life years (DALYs) (31) in 2015. The economic 
cost of diabetes is also high and will continue to rise; approximately 12% of the 
world’s total health expenditure was spent on diabetes in 2010 (32). The rising public 
health burden of diabetes has increased interest in the economic and societal costs 
of diabetes. In 2011, it was declared as one of four priority non-communicable 
diseases targeted by world leaders who recognised that a large proportion of the 
impact of diabetes can be prevented or reduced through the introduction of 
evidence-based interventions (33).    
2.3 Trends and prevalence of diabetes 
2.3.1 Global trends and prevalence of diabetes  
A systematic review examining worldwide trends in diabetes prevalence in 107 
countries between 1980 and 2008 concluded that diabetes was a rising global hazard, 
with the number of adults with diabetes having more than doubled over nearly three 
decades (3).  
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Findings from a more recent systematic review confirmed that over the past three 
decades, the global burden of diabetes had risen substantially in countries at all 
income levels (34). Using data from 146 countries and 751 population-based studies, 
the NCD Risk Factor Collaboration reported that between 1980 and 2014 there was 
a four-fold increase in the number of adults aged 18 years and over with diabetes. 
Over the period of interest, the worldwide prevalence of diabetes almost doubled in 
males (4·3% in 1980 to 9·0% in 2014) and increased by 60% in females (5·0% in 1980 
to 7·9% in 2014). The authors note a shifting from an excess prevalence in women in 
1980, to a higher male prevalence in 2014 (34).  
The rising prevalence of diabetes has been attributed to obesity, sedentary lifestyles, 
population growth and ageing population (2, 4). 
2.3.2 Trends and prevalence of diabetes in Europe 
In Europe, evidence suggests that the prevalence of diabetes is in line with global 
trends (35-39). A systematic review predicting trends in type 2 diabetes over a five 
year period (1995 to 2000) for seven European countries reported a slight decrease 
in diabetes prevalence in Finland; whereas a significant increase in prevalence was 
reported for Denmark, Spain, the UK, Germany, Italy and France (35).  
Estimates from more recent studies have confirmed that diabetes prevalence has 
continued to rise. Sharma et al., 2016 (36) extracted data from a national primary 
care medical records database to examine trends in the prevalence of type 2 diabetes 
in the UK between 2000 and 2013. The study found that the prevalence more than 
doubled over the study period, from 2.4% in 2000 to 5.3% in 2013.  The prevalence 
in males was approximately 30% higher than in females and estimates increased 
linearly with age (36).  
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Recent estimates from the Scottish Diabetes Survey (2014) reported that the 
prevalence of diabetes increased from 3.2% to 5.1% in Scotland between 2004 and 
2013 (37). Read et al. 2016 (37), explored possible factors for this increase by linking 
data from the Scottish national diabetes register to mortality records. The study 
reported that the incidence of type 2 diabetes remained relatively stable after 2004 
while mortality rates declined. The authors concluded that declining rates of obesity 
and a decrease in undiagnosed diabetes prevalence (due to earlier detection of 
diabetes) have caused incident rates to stabilise and suggest that improved survival 
is the leading contributor to the increasing diabetes prevalence (37). 
Elsewhere in Europe, Pereira et al. 2014 (38) pooled data from 18 national surveys to 
estimate age and gender-specific prevalence of self-reported diabetes over a 22 year 
period in Portugal. Between 1987 and 2009, diabetes prevalence remained 
approximately constant among younger adults (mean age of 30 years), while it 
increased in middle-aged (mean age 50 years) and older adults (mean age of 70 
years). Over this period, there was a three-fold increase in prevalence rates among 
males and a two-fold increase among females. In 2009, the prevalence of self-
reported diabetes was 9.4% and 8.6%, among males and females, respectively. An 
increase in obesity rates were suggested as possible explanations for the rising 
prevalence in Portugal (38). 
In Italy, Monesi et al., 2011 (39), extracted data from an administrative health 
database to examine temporal trends in diabetes prevalence among adults between 
2000 and 2007. Over the study period, the absolute number of individuals with 
diabetes increased by 47%, while the total population grew by 6.6%. The study found 
that diabetes prevalence increased on average, by 4.0% per year, from 3.0% in 2000 
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to 4.2% in 2007, while incidence rates did not change and mortality rates decreased 
by 3.0% per year. Ageing population, earlier detection of diabetes and improved 
survival were suggested as possible explanations for the rise in prevalence.  
2.3.3 Trends and prevalence of diabetes in USA  
Data from the USA suggest that trends in diabetes prevalence are comparable to 
estimates from Europe. Menke  et al., 2015 (40) used data from the National Health 
and Nutrition Examination Surveys (NHANES) to examine trends in the prevalence of 
diabetes (diagnosed, undiagnosed and prediabetes) among adults aged 20 years and 
over between 1988 and 2012. NHANES is an ongoing panel survey which collects data 
from nationally representative samples of non-institutionalized adults in the USA 
(41). Diagnosed diabetes was ascertained by self-report of a previous diagnosis by a 
doctor or other health professional. Over the study period, the prevalence of 
diagnosed diabetes increased significantly by 52%, from 6% in 1988-1994 to 9.1% in 
2011-2012. This increase was observed among the overall population and within 
each socio-demographic stratum (i.e. age-group, gender, ethnicity, education level, 
income level). The authors note that rates of diagnosed diabetes began to stabilise 
between 2007-2008 and 2011-2012. Improved detection of diabetes, an increase in 
obesity and an ageing population were suggested as possible explanations for the 
rise in prevalence (40).   
2.3.4 Prevalence of diabetes in longitudinal studies of ageing  
The world’s population is growing older. Changes in the demographic profile of many 
countries pose a major public health challenge, which include an increase in the 
number of people with chronic diseases. These changes will inevitably place rising 
demands on the health-care system. In response to this challenge, a number of large 
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longitudinal studies of ageing have been developed in various countries around the 
world. Findings from these studies are used to plan appropriate health, medical, 
social and economic policies. The prevalence of diabetes from four longitudinal 
studies of ageing are summarised in Table 2 to place results from the Irish 
Longitudinal Study on Ageing, TILDA (Chapter 4) in an international context. Each 
study includes community dwelling adults aged 50 years and over. Diabetes was 
ascertained by self-report of a previous diagnosis by a doctor or other health 
professional. 
Table 2. Prevalence of self-reported pervious doctor diagnosis of diabetes in four 
longitudinal studies of ageing 
 Total n Response 
rate (%) 
Diabetes 
type 
Prevalence 
 (%) 
Survey of Health, Ageing and Retirement in 
Europe (2004-2005)1(42) 
21,910 62 All 10.9 
English Longitudinal Study of Ageing  (2002-
2003)(43) 
11,523 70 All 8.1 
USA Health and Retirement Study (2004)(42) 18,580 86 All 16.4 
The WHO Study on Global Ageing and Adult 
Health (2007-2010)2(44) 
34,129 75 All 7.2 
1: Austria, Belgium, Denmark. France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland 
2: China, Ghana, India, Mexico, Russia, South Africa  
 
2.4 Health impacts of diabetes 
Much of the public health burden of diabetes can be attributed to complications that 
are secondary to diabetes (5). Chronic hyperglycaemia affects multiple organ systems 
in the body which over time, can lead to vascular complications. Generally, 
complications from diabetes can be classified as macrovascular or microvascular (5).  
2.4.1 Macrovascular complications of diabetes  
Macrovascular complications, which affect the large vessels of the circulatory 
system, include myocardial infarction, congestive cardiac failure, cerebrovascular 
disease and peripheral vascular disease (5). 
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Macrovascular complications are a major cause of death and disability in people with 
diabetes, accounting for 44% of fatalities in people with type 1 diabetes and 52% in 
people with type 2 diabetes (45, 46). After controlling for traditional CVD risk factors, 
people with diabetes are two to four times more likely to develop macrovascular 
complications relative to the general population and have a two-fold increased risk 
of stroke within the first five years of diagnosis compared with the general population 
(47, 48). 
2.4.2 Microvascular complications of diabetes  
Microvascular complications involve damage to the small blood vessels which can 
result in eye damage (diabetic retinopathy), nervous system damage (diabetic 
neuropathy) and renal system damage (diabetic nephropathy) (5). 
2.4.2.1 Diabetic retinopathy 
Diabetic retinopathy causes changes in the blood vessels of the retina that can lead 
to visual impairment and blindness (49). After 20 years of diabetes, nearly all those 
with type 1 diabetes and more than two-thirds of those with type 2 diabetes will have 
some degree of diabetic retinopathy (50).  
Diabetic retinopathy is the leading cause of vision loss in adults aged 20–74 years  
(51). From 1990–2010, it was the fifth most common cause of preventable blindness 
and also the fifth most common cause of moderate to severe visual impairment (52). 
Genz et al., 2010 (53) found that the risk of blindness in an individual with diabetes 
was 2.4 times that of an individual without diabetes. Visual impairment due to 
diabetic retinopathy has a significant impact on patients’ quality of life and can 
compromise their ability to manage their disease, which in turn can contribute to the 
occurrence of other diabetic complications and overall life expectancy (54). 
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2.4.2.2 Diabetic neuropathy  
Diabetic neuropathy is nerve damage that is due to diabetes. Up to 50% of people 
with diabetes develop nerve damage leading to foot ulcers and in severe cases, limb 
amputation (55).  
Diabetic neuropathy is a common cause of lower-leg amputations (49). In the USA, 
82% of all vascular-related lower extremity amputations are associated with diabetes 
(56). In Ireland, Buckley et al., 2012 (14) found that, the risk of an individual with 
diabetes undergoing lower-leg amputation was 22 times that of an individual without 
diabetes. 
2.4.2.3 Diabetic nephropathy  
Diabetic nephropathy is a progressive disease that occurs from damage to small 
blood vessels in the kidneys leading to the kidneys becoming less efficient or to fail 
altogether (49).  
Diabetic nephropathy occurs in approximately 40% of all people with diabetes and it 
is a leading cause of chronic kidney disease and end-stage renal disease (57). Kidney 
disease accounts for 21%  of deaths in people with type 1 diabetes and 11% of deaths 
in people with type 2 diabetes (57, 58). 
2.5 Prevalence of macrovascular and microvascular complications 
Differences in a number of factors can influence the estimated prevalence of 
diabetes complications including: the method used to detect complications, the age-
range of participants, severity and duration of diabetes and the distribution of risk 
factors. 
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The Cost of Diabetes in Europe-Type II study pooled data on 7000 people with type 
2 diabetes aged 30 years and over using data from different regions in Europe 
(Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the UK) in 
1998 (59). The study found that 72% of people had at least one diabetes-related 
complication. Among those with macrovascular complications, peripheral vascular 
disease was the most common, with a prevalence of 18%, followed by congestive 
cardiac failure (12%) and myocardial infarction (9%). Of those with microvascular 
complications, diabetic neuropathy was the most common, with a prevalence of 
28%, followed by diabetic retinopathy (20%) and diabetic nephropathy (20%). 
Furthermore, 2% of the sample were blind or had lower-leg amputation, and 1 % had 
end-stage renal failure requiring dialysis. The estimated annual healthcare cost per 
individual was €2834; 55% of this cost was attributable to hospital admissions (59).   
 
More recently, the Guideline Adherence to Enhance Care (GUIDANCE) study (60) 
carried out a cross-sectional analysis to determine the prevalence of macro-and 
microvascular complications among people with type 2 diabetes aged 18 years and 
over from eight countries in Europe (Belgium, France, Germany, Italy, Ireland, 
Sweden, the Netherlands, and the UK), between 2009 and 2010. Data were extracted 
from medical records in primary and secondary care. In total, 7,597 were included in 
the sample, of these 56% were male with a mean age of 66.5 years (SD 10.8). The 
study found that the overall prevalence of macrovascular complications was 24%; 
which ranged from 15% in Belgium to 38% in the UK. The overall prevalence of 
microvascular complications was 28%; which ranged from 22% in the UK to 37% in 
Germany. Prevalence figures for individual complications were not reported (60).  
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Data from NHANES 1999-2004 were used to assess the prevalence of diabetes-
related complications among adults with diagnosed type 2 diabetes aged 20 years 
and over in the USA (61). Complications were ascertained by self-report of a previous 
diagnosis by a doctor or other health professional. The study found that 
approximately two-thirds of people with diabetes had a previous diagnosis of at least 
one macrovascular or microvascular complication. The most common macrovascular 
complication was myocardial infarction (9.8%), followed by congestive cardiac failure 
(7.7%) and cerebrovascular disease (6.6%). The most common microvascular 
complication was chronic kidney disease (28%), followed by diabetic neuropathy 
(19%) and diabetic retinopathy (19%) (61).  
2.5.1 Prevalence of diabetic retinopathy  
Worldwide, it has been estimated that approximately 93 million individuals have 
some level of diabetic retinopathy and approximately one third are cases of vision-
threatening diabetic retinopathy (6). An individual participant meta-analysis of 
22,896 adults aged 20 to 79 years from 35 population-based studies in the USA, 
Australia, Europe and Asia (1980 to 2008) estimated that the overall prevalence of 
any diabetic retinopathy was 34.6% and for vision-threating diabetic retinopathy was 
10.2% in 2010 (62). Prevalence of any diabetic retinopathy and vision-threatening 
diabetic retinopathy were similar among males and females and were highest in 
African Americans and lowest in Asians. Prevalence of any diabetic retinopathy was 
higher in those with type 1 diabetes, compared to those with type 2 diabetes (77.3 
vs. 25.2 %)(62). 
Ruta et al., 2013 (63), collated evidence on the prevalence of diabetic retinopathy in 
13 developing and 20 developed countries between 1985 and 2012. The systematic 
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review included data from 72 studies and reported an overall median prevalence of 
28%. A wide variation in prevalence was observed between countries (63). In Europe, 
estimates from population-based studies ranged from 10% in Norway to 37.3% in the 
UK. Estimates from primary care-based studies ranged from 20% in Spain to 50% in 
Germany. The authors concluded that the review highlighted inconsistences 
between study methodologies and demonstrated that there was a lack of reliable 
population-based data describing the prevalence of diabetic retinopathy (63).  
2.6 Trends in blindness due to diabetic retinopathy   
Comparing the incidence of blindness due to diabetic retinopathy between countries 
is also limited due to differences in blindness criteria, differences in numerators 
(blindness in diabetes vs. blindness attributable to diabetes) and varying methods to 
estimate the population at risk. Hall et al. (64) used blind registry data to describe 
trends in the incidence of blindness due to diabetic retinopathy over a ten year 
period (2000-2009) among adults with diabetes in Fife, Scotland. A decrease in the 
crude incidence of blindness attributable to diabetes was observed, from 1.43 to 1.10 
per 100,000 total population and 59.7 to 23.9 per 100,000 population with diabetes 
(64).  
Elsewhere in the UK, a study from Leeds used data from visual impairment 
certification to analyse trends in the incidence of blindness secondary to diabetic 
retinopathy between 2008 and 2010 (65). In this study, the crude incidence of severe 
visual impairment decreased from 1.2 to 0.6 per 100,000 total population and 33.5 
to 16.9 per 100,000 population with diagnosed diabetes. The crude incidence of sight 
impairment decreased from 89.2 to 63.0 per 100,000 population with diagnosed 
diabetes (65).  
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Trends towards a declining incidence have also been observed in other parts of the 
UK (66) , Germany (53), Sweden (67), Israel (68, 69) and the USA (11). Downward 
trends have been attributed to a combination of factors, including improvements in 
disease management, earlier detection and treatment of diabetic retinopathy 
through the implementation of standardised retinopathy screening programmes and 
an increase in the number of diabetes cases (70, 71). It has been suggest that while 
the rates of some diabetes complications have decreased, the absolute number of 
cases will continue to rise because of the rising prevalence of diabetes (72). Longer 
duration of diabetes diagnosis is an established risk factor for diabetic retinopathy 
(73). After 20 years of diabetes, nearly all individuals with type 1 diabetes and more 
than two-thirds of individuals with type 2 diabetes will develop some degree of 
retinopathy (50). Therefore it is possible that the full impact of the diabetes epidemic 
has not yet been realised. 
2.7 Determinants of macrovascular and microvascular complications 
2.7.1 Diabetes related factors 
Hyperglycaemia and longer diabetes duration are the most common risk factors for 
diabetes complications (74-84). Diabetes duration reflects total glycaemic control 
and risk factor exposure over time (85). 
2.7.2 Cardiovascular risk factors  
Established risk factors for CVD such as hypertension, high cholesterol, and smoking 
further increase the likelihood of developing macro-and microvascular complications 
(86). The United Kingdom Prospective Diabetes Study (UKPDS) reported that the risk 
of myocardial infarction and stroke were higher in smokers and those with high 
cholesterol (87, 88). Prospective studies have also documented hypertension as a risk 
factor for the development macrovascular complications among individuals with 
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type 2 diabetes (87-90). Likewise, both smoking and hypertension have been 
identified as prominent risk factors in the development of neuropathy, nephropathy 
and retinopathy (77, 79-81, 89, 91).  
2.7.3 Socio-demographic factors 
Non-modifiable socio-demographic factors known to increase the risk of macro-and 
microvascular complications in people with diabetes include ethnicity (92, 93), 
increasing age (72, 75, 78, 87) and male gender (88, 94, 95). 
Lower socioeconomic status (SES), measured by income, education, employment, 
occupation, or living in an underprivileged area, has been associated with higher 
rates of fatal and nonfatal CVD disease among people with diabetes (96, 97) and an 
increase in the risk of the developing microvascular complications (79, 83, 98-101). 
Lower SES is considered to influence the development of such complications through 
health behaviours, access to care, and processes of diabetes care (98, 101-104). For 
example, among people with diabetes lower educational attainment has been 
associated with poorer disease management, fewer ophthalmologic visits and fewer 
foot examinations (98).  
2.8 Prevention of blindness due to diabetic retinopathy 
Visual impairment and blindness due to diabetic retinopathy are preventable in the 
vast majority of cases, through optimal treatment of diabetes, and control of risk 
factors such as hypertension and hypercholesterolemia (75, 105). Evidence from 
clinical trials documents the benefit of early laser treatment in preventing blindness 
among individuals with diabetic retinopathy (106-108). However, this condition is 
asymptomatic until it reaches an advanced stage and sight cannot be restored once 
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lost to diabetic retinopathy (50). Therefore, the success of treatment is dependent 
on early detection and timely referral (109).  
2.8.1 Screening for diabetic retinopathy  
Diabetic retinopathy meets the World Health Organization (WHO) criteria for 
screening (110, 111). First, diabetes-associated visual impairment is an important 
public health problem and the natural history of diabetic retinopathy is well defined 
and understood. Second, diabetic retinopathy is asymptomatic until it reaches an 
advanced stage therefore it has a latent stage. A universally accepted and effective 
treatment is available (third criteria); screening detects early sight-threatening eye 
lesions which can be treated effectively with laser photocoagulation. Finally, retinal 
screening has been shown to be cost effective in terms of sight years preserved 
compared with no screening (112) and the risk of moderate to severe visual 
impairment due to diabetic retinopathy can be reduced by up to 50% (108). As a 
result, international policy and clinical guidelines recommend the implementation of 
systematic diabetic retinopathy screening programmes as part of national diabetes 
strategies (113, 114).  
2.9 Diabetic retinopathy screening programmes 
In 1989, a group of patient representatives, governmental representatives and 
diabetes experts met to discuss the growing problem of diabetes across Europe. 
Recommendations from this meeting were published in the St Vincent Declaration in 
1990 (113). The declaration outlined key five year targets for diabetes, which were 
'to elaborate, initiate and evaluate comprehensive programmes for detection and 
control of diabetes and its complications' and to 'implement effective measures to 
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reduce new blindness due to diabetes by one third or more', among other priorities 
relating to CVD, renal disease and amputations (113).  
In response to this, representatives from 21 European countries established a 
protocol for the implementation of diabetic retinopathy screening in 1991 (115). The 
working group concluded that the cost of organising nation-wide screening was 
substantially lower than the costs involved in late treatment and supportive care for 
people who had lost their sight due to diabetic retinopathy (115). In 2005, a 
conference took place in Liverpool to review progress of goals that were outlined in 
the St Vincent’s Declaration. The Liverpool Declaration reiterated the importance of 
screening (114) and recommended that the risk of visual impairment due to diabetic 
retinopathy should be reduced through ‘the introduction of systematic screening 
programmes that will reach at least 80 % of the population with diabetes; the 
employment of trained professionals and personnel; and the provision of universal 
access to laser therapy’ (114). Since retinal screening is crucial for early detection and 
timely treatment, many countries have introduced population-based screening 
programmes as part of their national diabetes strategy (116, 117). 
2.9.1 Diabetic retinopathy screening services in Ireland 
In Ireland, the lack of a national population-based retinal screening programme had 
been highlighted as a deficit in diabetes care for over two decades (118). Screening 
was delivered on a limited basis by a number of local services using different models 
of service provision (119). In 2002, the Diabetes Service Development Group (120) 
outlined a proposal for the implementation of a national screening service in Ireland. 
Four years later, the Department of Health and Children recommended a structured 
diabetic retinopathy screening programme as a priority for people with diabetes. This 
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priority was emphasized again by the Expert Advisory Group (EAG) for Diabetes (119) 
in 2007; during the same year a National Retinopathy Screening committee was 
established to develop a strategy for the development and implementation of a 
national population-based retinal screening programme (121). The need for a 
national population-based retinopathy screening programme was highlighted again 
in 2010 when the National Clinical Programme for Diabetes (NCPD) was established 
(7). The implementation of this service was a key priority area for the NCPD given the 
previous groundwork of the EAG for Diabetes. In 2011, the development and 
implementation of a national population-based retinal screening programme was 
handed over to the National Screening Service (122).   
2.9.2 The national diabetic retinopathy screening programme  
In 2013, Diabetic Retinascreen was introduced to provide free, annual retinal 
screening (and where necessary, treatment) to anyone aged 12 years or older with 
diagnosed diabetes. The overall aim of the screening programme is to reduce the risk 
of sight loss among people with diabetes by the early detection and treatment of 
sight-threatening retinopathy (122). Implementation of Diabetic Retinascreen 
changed the provision of diabetic retinopathy screening in Ireland by providing 
universal screening access for people with diabetes, standardising the delivery of 
screening and improving the quality of screening (123). Estimates suggest that the 
programme could prevent 235 cases of blindness and 2,500 cases of visual 
impairment over the first 4.5 years of implementation, if universal uptake is achieved 
(124). This reduction in diabetes-related morbidity will benefit the individual and 
society by improving quality of life and by reducing the public health burden of 
blindness due to diabetic retinopathy (122, 123). 
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2.10 Uptake of retinopathy screening programmes 
Although evidence shows that retinal screening is effective at detecting unrecognised 
sight-threatening retinopathy, the success of any screening programme depends on 
continued high levels of uptake; a high proportion of the target population has to be 
screened so enough cases of sight-threatening diabetic retinopathy can be detected 
and treated (125). However, unlike most other screening programmes, screening for 
diabetic retinopathy targets a population with a predefined illness who already face 
significant healthcare and self-management demands. Retinal screening is a life-long 
commitment for people with diabetes. 
Consequently, ensuring high uptake to a retinal screening programme is challenging 
(116, 126) and screening rates consistently fall far below recommended levels. 
Internationally, non-attendance to retinopathy screening has been highlighted as an 
issue (71, 127-154); with non-attendance rates ranging from 24% in the USA to 44% 
in the UK. Within the UK, there is wide variability in screening uptake between 
primary care practices and regions (140).  Issues with uptake have also been 
previously highlighted by regional screening programmes in Ireland, with non-
attendance rates ranging from 20% to 51% (155-157). During the early 
implementation phase of Diabetic Retinascreen, programme uptake has been 
highlighted as a concern. In the first round of screening, of the 154,734 people invited 
to participate in the programme 73,201 people (47%) attended a screening 
appointment (17). 
2.10.1 Barriers to screening attendance  
Research has shown that people least likely to attend screening appointments are at 
greater risk of sight-threatening retinopathy because they are more likely to have 
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other risk factors, including poor glycaemic and blood pressure control (147, 154). 
Various studies have demonstrated lower attendance rates among younger adults 
(130, 133, 138, 142, 145, 149, 150, 154), people with type 1 diabetes (149, 150) and 
those with a shorter time since diabetes diagnosis (127, 130, 133, 135, 136, 150) . 
Social deprivation (138, 139, 142, 145, 149, 150) and relative lack of education (127, 
130, 136) have also been associated with poor uptake of screening; with those from 
the lowest socio-economic groups being less likely to attend.  
Barriers to screening attendance are multifactorial and vary in different populations 
and healthcare systems. For example, cultural barriers such as language have been 
reported in ethnically diverse populations (138, 140, 143). For those living in rural or 
remote locations, difficulties with access due to transportation issues are often cited 
as a barrier to attendance (132, 138, 140, 141, 144). In countries such as the USA 
(127-129, 131, 132, 148) and Australia (146), lack of health insurance and financial 
constraints are common barriers to screening attendance. However, some barriers 
to diabetic retinopathy screening attendance have been highlighted consistently in 
the international literature.  
Common individual-level barriers include, limited awareness of diabetic retinopathy 
(130, 131, 136, 144, 146, 157), lowered perception of risk (127-129, 131, 132, 144, 
146), psychological factors such as fear of diagnosis (137, 144), and practical barriers 
such as the side effects from mydriasis drops (141, 146, 157), work commitments 
(141, 144, 146) and competing priorities (137, 145, 148). Lewis et al. 2007 (144) 
carried out a qualitative study to explore influences on retinopathy screening 
attendance among patients and providers at three ophthalmic outpatient clinics in 
the UK. The study found that a lack of awareness was the greatest barrier to 
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attendance. However, these deficits in knowledge were quite specific as participants 
knew diabetes could affect the eyes but were not aware that it could lead to 
blindness. Additionally, a lack of awareness regarding the asymptomatic nature of 
diabetic retinopathy was a common barrier cited by participants. The fear of vision 
loss motivated screening attendance, however, the fear of being diagnosed with 
advanced-stage retinopathy was an important deterrent for attendance (144). 
Similar barriers were reported from focus groups of non-attenders to retinopathy 
screening carried out at a medical centre in the USA (129).  Participants in this study 
were unaware that the late stages of diabetic retinopathy were asymptomatic and 
that floaters or “spots” were an important symptom of severe retinopathy (129).  
Provider-level barriers have also been explored in the literature and include, 
inconvenient screening location (138, 148), restricted availability of appointments 
(132, 138, 141) and long waiting times (136, 138, 144). Moreton et al. 2017, (138) 
investigated provider-levels factors that influenced uptake to the English national 
diabetic retinopathy screening programme among patients at 79 primary care 
centres. The study suggested that the variation in screening uptake between 
practices could be partly explained by differences in the availability and flexibility of 
screening appointments offered by providers, the convenience of the screening 
location and a general interest taken by the primary care centre in diabetes care 
(138).  
2.10.2 Facilitators of screening attendance 
Factors that have been shown to positively influence uptake to retinopathy screening 
programmes include a fear of impaired vision (136, 144, 146), a recommendation 
from a healthcare provider (129, 135, 136, 146, 157), mobile screening service (138, 
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150) and improved communication between screening providers (137, 140). In 
Australia, Lake et al. 2017 (146) explored facilitators to retinopathy screening 
attendance among people with type 2 diabetes. The study found that the benefits of 
screening, such as early detection of diabetic retinopathy and feeling reassured 
facilitated attendance. Additionally, participants who were advised by their GP to 
have an eye examination, or were referred to an eye specialist for screening at 
diagnosis, reported initiating screening in a timely manner (146).  
2.10.3 Factors influencing screening attendance in Ireland 
In Ireland, there is a dearth of information on the barriers to or facilitators of 
screening attendance. One study carried out by Dervan et al., 2008, (157) explored 
factors that influenced uptake of retinopathy screening in two hospital-based 
diabetes clinics in Dublin. A questionnaire covering demographics, diabetic medical 
history and the knowledge of and attitudes to diabetic retinopathy was administered 
to all adults who were due to attend the diabetes clinic over a two month period 
(December 2001 to January 2002). Of the 209 patients with diabetes included in 
analysis, 169 (81%) had attended retinopathy screening in the previous 12 months. 
In line with existing literature, lack of knowledge regarding the need for retinopathy 
screening and the effect of mydriasis drops in prohibiting driving were the main 
barriers to attendance. A recommendation from a healthcare professional about the 
importance of regular retinopathy screening and an acceptance that screening was 
part of usual diabetes care were predictors of attendance.  
2.10.4 Consequences of non-attendance  
Non-attendance at diabetic retinopathy screening is costly for the individual with 
diabetes and the health service. People who do not attend for screening frequently 
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are at increased risk of sight-threatening diabetic retinopathy and the risk increases 
with the duration that an individual is unscreened (71). Non-attendance has major 
financial consequences. In the UK, it has been estimated that non-attendance costs 
approximately £78 000 (€97 000) over one year based on data from one primary care 
trust Lawrenson (158). 
2.11 Summary  
Diabetes is a chronic disease with serious complications and is an important public 
health problem. It is one of four priority non-communicable diseases targeted for 
action by world leaders. Globally, prevalence rates have increased rapidly over the 
past three decades.  
Within-country estimates of the total population with diabetes and the proportion 
of people who have developed complications are needed to inform public health 
policy on care for people with diabetes. In the absence of a diabetes register, 
estimates of diabetes and related complications are generated from available data 
sources. 
The systematic review (Chapter 3) compiled available epidemiological data regarding 
the public health burden of diabetes in Ireland. Critical assessment of the current 
evidence base also enabled identification of the best available data sources to use in 
this thesis. Data identified in the review are used to describe trends in the prevalence 
of diagnosed diabetes over a 17-year period (1998 to 2015) (Chapter 3). In addition, 
estimates of the population with diabetes were required to calculate incidence rates 
of visual impairment and blindness due to diabetes in the population with diabetes 
(Chapter 6).  
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Similar to other countries, Ireland is experiencing an increase in the ageing 
population which will inevitably result in an increase in the prevalence of chronic 
illness. It is important that the magnitude of diabetes and its complications is 
assessed within the older population in Ireland. Findings from Chapter 4 will provide 
robust data to plan appropriate health, medical, social and economic policies. Many 
determinants for macro-and microvascular complications in people with diabetes 
exist. The roles of clinical and socio-demographical risk factors for macro-and 
microvascular complications in people with diabetes are well documented but there 
is limited evidence in the Irish context. This deficit in knowledge is addressed in 
Chapter 5. Identification and treatment of risk factors can delay or prevent the 
development of diabetes related complications.  
Rates of blindness due to diabetic retinopathy have been reported from many 
countries and have been published in peer-reviewed journals. In Ireland, rates of 
blindness due to diabetic retinopathy in the total population were calculated in 1998 
and 2003, using data from the NCBI. Contemporary data is important for measuring 
the impact of improvements in care and for monitoring the progress of Diabetic 
Retinascreen (Chapter 6). Evaluation of the implementation of a public health 
intervention aimed to prevent diabetes related blindness (Chapter 7) is an essential 
first step to understanding the effectiveness of a national screening programme in 
the Irish health care setting. 
The research in this thesis provides reliable data on the incidence prevalence of 
diabetes and its complications. Findings will play an important role for population 
health by describing the public health burden of diabetes in Ireland and providing 
recommendations for the on-going implementation of Diabetic Retinascreen. In 
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addition, this thesis will provide key source data to identify trends in diabetes and its 
complications at national level to facilitate diabetes program planning and to inform 
policy decisions including resource allocation. 
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3.1. Abstract 
Background: Accurate estimates of the burden of diabetes are essential for future 
planning and evaluation of services. In Ireland, there is no diabetes register and 
prevalence estimates vary. The aim of this review was to systematically identify and 
review studies reporting the prevalence of diabetes and complications among adults 
in Ireland between 1998 and 2015 and to examine trends in prevalence over time.    
Methods:  A systematic literature search was carried out using PubMed and Embase. 
Diabetes prevalence estimates were pooled by random-effects meta-analysis. 
Poisson regression was carried out using data from four nationally representative 
studies to calculate prevalence rates of doctor diagnosed diabetes between 1998 and 
2015 and was also used to assess whether the rate of doctor diagnosed diabetes 
changed over time.  
Results: Fifteen studies (8 diabetes prevalence and 7 complication prevalence) were 
eligible for inclusion. In adults aged 18 years and over, the national prevalence of 
doctor diagnosed diabetes significantly increased from 2.1% in 1998 to 5.2% in 2015 
(p trend ≤ 0.001). The prevalence of diabetes complications ranged widely depending 
on study population and methodology used (6.5-25.2% retinopathy; 3.2-32.0% 
neuropathy; 6- 9.1% nephropathy).   
Conclusions: Between 1998 and 2015, there was a significant increase in the 
prevalence of doctor diagnosed diabetes among adults in Ireland. Trends in 
microvascular and macrovascular complications prevalence could not be examined 
due to heterogeneity between studies and the limited availability of data. Reliable 
baseline data are needed to monitor improvements in care over time at a national 
level. A comprehensive national diabetes register is urgently needed in Ireland.  
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3.2 Background 
Diabetes is a serious global public health issue which has been described as the most 
challenging health problem in the 21st century (1, 2). Cases of diabetes have 
progressively increased worldwide; between 1980 and 2008 there was a two-fold 
increase in the number of adults with diabetes (160). Type 2 diabetes is the main 
driver of the epidemic, accounting for approximately 90% of all cases (2). The 
increasing burden of diabetes is driven primarily by rising levels of obesity and an 
ageing population (2, 30). To date there is no national surveillance programme, or 
national population-based survey of diabetes in Ireland. Therefore it is difficult to 
quantify or monitor the impact of diabetes at a national level. Estimates from the 
International Diabetes Federation (IDF) (2013) suggest that the prevalence of 
diabetes is in line with global trends. In 2000, the IDF estimated that the prevalence 
of diabetes was 3.2% (161), this had increase to 6.5% in 2103 (2).  
Diabetes places a significant burden of care on the individual, health care 
professionals and the wider health system (1, 3). Individuals with diabetes are two to 
four times more likely to develop CVD relative to the general population and have a 
two- to five-fold greater risk of dying from these conditions (47, 48). Diabetes is a 
significant cause of blindness in adults, non-traumatic lower limb amputations and 
end-stage renal disease resulting in transplantation and dialysis (2). 
Understanding the epidemiology of diabetes is essential to identify public health 
priorities. Accurate estimates of the burden of diabetes are essential for future 
planning and evaluation of services. While the IDF provides prevalence estimates for 
countries and regions, there are substantial variations in time trends as estimates are 
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based on imputations (162, 163). To date, estimates of diabetes prevalence in Ireland 
have been largely based on data from 2007 derived from SLÁN (164). Country specific 
prevalence rates have also been reported in the grey literature (2); however these 
estimates have been extrapolated using data from the UK. The Euro Diabetes Index 
(2014) stated that there was a lack of reliable data to monitor diabetes related 
complications in Ireland (13). To date, a comprehensive overview of the diabetes 
situation in Ireland has not been carried out. Therefore the rationale for carrying out 
this systematic review is to provide a comprehensive understanding of the diabetes 
situation in Ireland and to highlight current gaps in existing knowledge to inform 
future research. The aims of this review are to (1) to systematically identify and 
summarise studies describing the prevalence of diabetes and the most common 
microvascular (retinopathy, neuropathy and nephropathy) and macrovascular 
complications among adults in Ireland between 1998 and 2014; and (2) explore 
trends in diagnosed diabetes prevalence between 1998 and 2015. 
3.3 Methods 
This review was produced according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews and meta-
analyses (165). Key words and study eligibility criteria were determined a priori.   
3.3.1 Search strategy 
Both peer-reviewed journal articles and reports were considered for this review. A 
systematic literature search was carried out in PubMed and Embase databases to 
identify relevant studies reporting the prevalence of diabetes, microvascular or 
macrovascular complications among adults within the Republic of Ireland.  Keywords 
and Medical Subject Headings (MeSH) terms included Ireland, prevalence, diabetes, 
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microvascular, retinopathy, neuropathy, nephropathy, macrovascular and 
cardiovascular disease. Keywords were combined using the AND/OR operators 
(Appendix 3; supplementary file 1). Titles and abstracts of the resulting literature 
were screened for further consideration. Reference lists of articles were also 
examined to identify potentially relevant studies. In addition, a Google search was 
conducted using the keywords prevalence, diabetes, retinopathy, neuropathy, 
nephropathy and Ireland to identify relevant grey literature. Searches were carried 
out between January 2014 and March 2014. A second search was carried out in 
December 2015 to ensure the review included all up to date relevant information. 
3.3.2 Inclusion criteria  
Studies were eligible for inclusion if they met the following criteria: (1) conducted in 
the Republic of Ireland between 1998 and 2014; (2) cross-sectional study design or 
baseline data from longitudinal studies; (3) prevalence estimates reported for adults 
aged ≥ 18 years, including men and women; (4) data provided on diabetes prevalence 
(including a self-report of a previous doctor diagnosis and undiagnosed diabetes) 
and/or the prevalence of microvascular complications (retinopathy, neuropathy, 
nephropathy) or macrovascular complications (myocardial infarction, congestive 
heart failure, stroke or  TIA) in persons with diabetes; (5) if prevalence data were not 
reported, sufficient detail to calculate the numerator and denominator was 
provided; (6) the total sample size was ≥ 200; (7) adequate information was reported 
on the methods used. 
3.3.3 Exclusion criteria 
Studies containing participants from Northern Ireland, restricted to a specific sub-
population (including hospital-based studies), solely focused on Type 1 diabetes, pre-
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diabetes or gestational diabetes were excluded from this review. Model estimates of 
prevalence were also excluded. If multiple articles provided information on a single 
study, the article detailing the most comprehensive data was selected. Full text 
articles were retrieved for all potentially eligible studies and were independently 
reviewed by three authors (MT, MG, and KO’N).  
3.3.4 Data abstraction and quality assessment  
For each eligible study, three reviewers (MT, MG, and KON) individually collected 
relevant information using a structured data extraction form. The methodological 
quality of each included study was assessed using a critical appraisal checklist for 
studies used in systematic reviews addressing questions of prevalence (166). This 
appraisal tool was developed to specifically examine the internal and external validity 
of prevalence data included in systematic reviews. Methodological quality was 
considered ‘low’ if three or fewer criteria were met, ‘moderate’ if four to six criteria 
were met and ‘high’ if seven to nine criteria were met. Articles were not excluded on 
the basis of quality. Any inconsistencies in data abstraction and quality assessment 
between reviewers were resolved through consensus.  
3.3.5 Statistical analysis  
A meta-analysis was carried out using STATA version 13.1 (StataCorp, College Station, 
TX, USA). Studies were grouped into four categories: diagnosed diabetes among 
adults aged 18+ years; diagnosed and undiagnosed diabetes among adults aged 45+ 
years; diagnosed diabetes among adults aged 45+ years; undiagnosed diabetes 
among adults aged 45+ years.  Pooled estimates of diabetes prevalence and 95% 
confidence intervals (95% CI) were calculated. Trends in pooled prevalence could not 
be explored as there was a lack of available data from different time points; therefore 
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an overall estimate was provided for each group. Heterogeneity between studies was 
assessed by the Chi-square based Q test and I2 statistic. Potential publication bias 
was evaluated by the Egger’s test. A two-tailed p <0.05 was regarded to be 
statistically significant. High heterogeneity was found among studies reporting 
diabetes prevalence (I2 ≥75%, p-value < 0.01) hence, pooled estimates were 
calculated using random-effects model using the method of DerSimonian and Laird 
(167). The results from the meta-analysis were presented in a forest plot. To 
determine the robustness of the results, a sensitivity analysis, based on high quality 
studies, was carried out. A meta-analysis of the prevalence of diabetes complications 
was inappropriate; factors which influence prevalence estimates (e.g. time since 
diabetes diagnosis, type of diabetes, method of diagnosis) either varied between 
studies or were not reported. Instead a narrative synthesis provides a summary of 
relevant data.  
3.3.5.1 Trends in diagnosed diabetes 
As trends in diabetes prevalence could not be calculated by meta-analysis, original 
datasets from four national population based studies (16-19), identified during the 
literature search were obtained and analysed. In each dataset, diabetes was defined 
by a self-report of a previous doctor diagnosis. A detailed description on study 
methodology can be found elsewhere (18, 168). Using data from these national 
surveys, multivariate Poisson regression models were undertaken to impute annual 
gender and age-specific (18-39 years, 40-69 years, ≥ 70 years) rates of diagnosed 
diabetes and to assess trends over time. The dependent variable was the number of 
cases of diagnosed diabetes and the exposure variables were year of data collection 
and age group. An interaction term between calendar year and age group was 
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considered to explore whether the rates of change over time differed across age 
groups; a non-significant interaction indicated a common linear trend in prevalence. 
The predict command was used post analysis to calculate the expected rates of 
diagnosed diabetes for each calendar year of the study. The gender and age-specific 
predicted rates were applied to 2004–2015 population data so the absolute number 
of diabetes cases could be obtained. Annual population estimates were obtained 
from the Central Statistics Office (CSO), Ireland (30). A census took place in Ireland in 
2002, 2006 and 2011; data for other study years were CSO inter-censal estimates 
(30). Prevalence was calculated by dividing the number of expected cases of doctor 
diagnosis of diabetes by the total study population and was expressed as a 
percentage with 95% CI. Prevalence estimates were presented graphically in Excel.   
3.4 Results 
3.4.1 Study selection  
Results of the literature search and the selection process are summarised in Figure 
3. One report (169) provided two estimates for diabetes prevalence from two 
separate studies (16, 17). In total, 15 studies were eligible for inclusion; 8 reporting 
estimates on diabetes prevalence and 7 reporting estimates on complication 
prevalence. Of the included studies, the methodological quality was considered 
moderate in nine studies and high in the remaining studies (Appendix 3; 
supplementary file 2).  
3.4.2 Characteristics of selected studies 
Characteristics of studies that reported the prevalence of diabetes or diabetes 
complications are presented in Table 3 and Table 4. In all included studies, data 
collection were carried out between 1998 and 2011. Studies varied in terms of the 
study design, setting (national vs. regional), sampling approach and study quality. Of 
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the 8 studies reporting on diabetes prevalence, five articles had been published in 
peer-reviewed journals (164, 170-173), while three estimates were reported in two 
national reports (169, 174). Of the 7 studies reporting diabetes complications, six had 
been published in peer-reviewed journals (14, 175-179), while one audit (180) 
provided data on the prevalence of diabetes related complications. Five studies 
utilised an objective data source to ascertain the prevalence of complications (14, 
175, 176, 179, 180). The diagnostic criteria for complications was unclear in three 
studies (177, 178, 180) whereas the remaining four used validated diagnostic criteria 
to identify cases (14, 175, 176, 179), however these criteria differed between studies 
reporting on the same complication.  
3.4.3 Prevalence of diabetes in included studies 
Table 5 reports the prevalence of diabetes by study. Individual and summary 
estimates, based on a random-effects meta-analysis are illustrated in Figure 4. There 
was significant heterogeneity in all groups. Sensitivity analysis only showed lower 
heterogeneity in combined prevalence rates for undiagnosed and diagnosed 
diabetes among adults aged over 45 years (I2 ≥25%, p=0.36); with a pooled 
prevalence of 9.2% (95% CI: 8.6-9.8) (Appendix 3; supplementary file 3). According to 
the Egger's test, there was no evidence of publication bias (p=0.27).  
3.4.4 Trends in the prevalence of diagnosed diabetes over time 
In adults aged 18 years and over, the prevalence of diagnosed diabetes increased 
from 2.2% (95% CI: 1.7%-2.7%) in 1998 to 5.2% (95% CI: 5.1%-5.3%) in 2015 
(ptrend=<0.001); representing an absolute mean increase of 0.17% per year. In 2015, 
the incidence of diagnosed diabetes was 0.2/100 population.  
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Figure 5 illustrates the age-specific prevalence of self-reported diagnosed diabetes 
from 1998 to 2015.  In adults aged between 18 and 39 years, the prevalence of self-
reported doctor diagnosed diabetes remained stable between 1998 and 2015 in both 
men and women; ptrend >0.05. However, there was a significant increase in 
prevalence among men aged 40 to 69 years between 1998 (3.5% [95% CI: 3.4%-
3.6%]) and 2015 (6.6% [95% CI: 6.5%-6.7%]; ptrend <0.001). The prevalence of diabetes 
also increased among women in the same age group over the same time period 
(1998- 2.5% [95% CI: 2.4%-2.5%] to 2015-4.2% [95% CI: 4.1%- 4.3%]; ptrend <0.001). In 
those aged 70 years and over, an upward trend in prevalence among both men 
(1998- 8.2% [95% CI: 8.0%-8.3%] to 2015-15.1% [95% CI: 14.8%-15.2%]) and women 
(1998- 4.7% [95% CI: 4.5%- 4.8%] to 2015- 10.7% [95% CI: 10.5%- 10.8%]) was also 
observed; ptrend <0.001.  
3.4.5 Prevalence of microvascular and macrovascular complications  
Table 6 describes the prevalence of microvascular and macrovascular complications 
in each included study. Five out of seven studies reported the prevalence of 
retinopathy (175, 177-180). Among people with type 2 diabetes, a population based 
study reported the prevalence of diabetic retinopathy to be 8.5% in 2009-2011 (178); 
a regional study, carried out among primary care patients, found a higher prevalence 
of 24.8% (179); however this estimate included patients with Type 1 and 2 diabetes  
and was based on objective data. A similar estimate (25.6%) was reported in a 
comparable cohort of primary care patients in a different region (180).  
In terms of diabetes-related neuropathy, a divergence in the reported prevalence 
between studies was also observed. Data from 12 primary care centres in the West 
of Ireland indicated a prevalence of past documented neuropathy to be 3% (176). On 
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the other hand, a population-based study reported a prevalence of 14.6% (178). 
These patients had similar average duration since diagnosis (5.0 years (178) vs. 7.8 
years (176)); however, the latter estimate was based on self-reported data. 
Prevalence rates for leg amputations were 1.7% among primary care patients with 
diabetes (180). In contrast, the prevalence of non-traumatic lower leg amputation 
was lower (0.2%) in a population-based study which utilised national hospital 
discharge data (14).  
With reference to nephropathy, prevalence among those with type 2 diabetes was 
similar in two studies (177, 178). In the three studies presenting data on 
macrovascular complications, a marked difference in prevalence was observed. A 
primary care audit reported a prevalence of 3.5% in patients with Type 1 and 2 
diabetes (180). In contrast, among those with type 2 diabetes, a population based 
study reported a higher prevalence of 15.1% (178).  
3.5 Discussion 
 
3.5.1 Main findings 
This systematic review is the first study to compile all available evidence reporting 
the prevalence of diabetes (diagnosed and undiagnosed) and related complications 
(microvascular and macrovascular) among adults in Ireland between 1998 and 2015. 
Fifteen studies (eight describing diabetes prevalence and seven describing 
complication prevalence) were included.  
Similar to other systematic reviews (38, 181, 182); comparability between studies 
was limited due to differences in study population, sampling methods and diagnostic 
criteria. Additionally, substantial statistical heterogeneity was detected between 
studies reporting the prevalence of diabetes; therefore our pooled estimates have to 
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be interpreted with caution. Sensitivity analysis, based on study quality, lowered the 
heterogeneity of combined prevalence rates for undiagnosed and diagnosed 
diabetes among adults aged over 45 years. However, this may reflect variability 
between prevalence estimates rather than study quality. Trends in diabetes 
prevalence could not be explored by meta-analysis, therefore, original data from four 
population-based national studies (16-19) were obtained to explore time trends in 
doctor diagnosed diabetes prevalence between 1998 and 2015. Over a seventeen 
year period, we observed an important increase in the national prevalence of self-
reported diagnosed diabetes in Ireland. 
Consistent with previous research (183-185) trends in the prevalence of self-reported 
diagnosed diabetes remained constant in adults aged 18 to 39 years, while an 
increasing prevalence was observed in the older age groups. We were unable to 
distinguish between the various types of diabetes in this review; however it can be 
assumed that type 2 diabetes is driving the increase in prevalence as it accounts for 
90% of all diabetes cases (1, 2). The prevalence of diabetes was consistently higher 
in males compared to females. Evidence suggests that men are at a higher risk of 
developing type 2 diabetes as they develop diabetes at a lower BMI, are more 
predisposed to central fat deposition and are more prone to insulin resistance (186). 
Therefore, men are more like to develop type 2 diabetes in response to increasing 
levels of obesity (187). On the other hand, the higher prevalence in the male 
population may reflect preferences in diagnostic methods. Evidence has highlighted 
that the prevalence of FPG diagnosed diabetes is higher among men, whereas 
women are more commonly diagnosed by a 2-hour plasma glucose test (188). While 
it is not possible to determine the method of diabetes diagnosis in this review; it is 
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important to consider how these gender differences may influence diagnosed 
diabetes prevalence estimates over time.  
Similar to diagnosed diabetes, trends in the prevalence of undiagnosed diabetes 
could not be explored by meta-analysis as only two nationally representative studies 
had relevant data (164, 189). The prevalence of undiagnosed diabetes, based on 
HbA1c, decreased from 2.8% in 2007 to 0.9% in 2009-2011 among adults aged ≥45 
years and ≥50 years, respectively. While the prevalence of diagnosed diabetes 
increased from 6.1% in 2007 (164) to 8.6% in 2009-2011 (172). This shift from 
undiagnosed to diagnosed diabetes prevalence has also been observed in a study 
carried out in Germany (163). This decrease in undiagnosed diabetes prevalence may 
be attributable to earlier detection of diabetes (163). In Ireland, screening high risk 
patients for type 2 diabetes has been encouraged since the introduction of national 
guidelines for diabetes-care in 2002 (120). Another study based on 29144 adults aged 
45-75 years with private health insurance, reported the prevalence of undiagnosed 
diabetes to be 1.8% in 2009-2012 (190) . However this estimate was derived from 
FPG; evidence suggests that HbA1c criteria may underestimate prevalence compared 
with estimates using FPG (183, 188, 191). 
The prevalence of diabetes complications varied substantially between studies 
therefore comparisons between studies have to be interpreted with caution. These 
variations may be attributable to differences in disease duration, study setting 
(primary care vs. population- based) or heterogeneity in the criteria used to diagnose 
macrovascular and microvascular complications. Objective data describing the 
national prevalence of diabetic retinopathy was not available however, regional data 
on diabetic retinopathy showed that approximately 25% of primary care patients had 
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been diagnosed with this condition (179, 180). This estimate is higher than a previous 
hospital-based study based on patients with type 2 diabetes (14.8%) (192) and 
primary care data from the UK  (19.6%) (63) but lower than global prevalence 
estimates (34.6%) (6). Though, caution has to be applied when interpreting the 
results as both regional studies included in this review reported a low uptake rate of 
retinopathy screening at approximately 50% (63, 179). Additionally, characteristics 
between attenders and non-attenders were not compared in either study; hence it 
is possible that there were systematic differences between the two groups. Healthier 
people are more likely to participate in research; therefore the prevalence of diabetic 
retinopathy may have been underestimated. As a national screening programme for 
diabetic retinopathy was introduced in 2013 (122), future estimates based on this 
national programme may be more reliable.  
3.5.2 Strengths and limitations 
The strengths and limitations of this systematic review should be noted. Both peer-
reviewed articles and estimates detailed in the grey literature were included to limit 
the impact of publication bias. Original data from four national studies were obtained 
so trends in diagnosed diabetes prevalence could be examined over a 17 year period. 
Although response rates were below the optimal rate of 70%, the representativeness 
of each study has been demonstrated previously (18, 193), so it can be assumed that 
the results presented can be generalised to the Irish population.  
However, several limitations need to be acknowledged.  Firstly, studies included in 
this review were of moderate to high quality; however, six of the included studies 
relied on self-reporting to determine the prevalence of diagnosed diabetes and one 
study relied on self-reporting to determine the prevalence of diabetes related 
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complications. This approach is prone to misclassification bias which can result in an 
inaccurate estimation of prevalence (194). When compared to medical records, data 
from self-report have been shown to underestimate the prevalence of diabetic 
retinopathy (195). However, moderate to high levels of agreement between diabetes 
prevalence and self-report have been shown in several studies (196-198) . Although 
only data on self-reported diabetes were available, results from trend analysis are in 
line with other developed countries. Secondly, without the inclusion of undiagnosed 
diabetes in our trend analysis, we acknowledge that diabetes prevalence is 
underestimated. Finally, significant increases in diagnosed diabetes prevalence were 
observed over time but these increases may be attributed to heightened awareness 
among patients, changes in clinical practices including increases in screening for type 
2 diabetes and better survival rates for patients with diabetes (199). However, there 
is a lack of data on mortality rates among people with diabetes in Ireland; therefore 
it is not possible to determine whether our increasing trends in prevalence are due 
to improved health outcomes in those with diabetes.  
3.5.3 Conclusions  
This review provides the first comprehensive overview of the burden of diabetes in 
Ireland. In the absence of a national diabetes register, the findings in this review 
provide a robust estimate of the trends in prevalence of doctor diagnosed diabetes 
among the adult population in Ireland. Findings from this review are in accordance 
with the Euro Diabetes Index (2014) (13); there is a lack of information relating to the 
prevalence of undiagnosed diabetes, macrovascular and microvascular 
complications. Interpretation of available data was limited due to inconsistencies in 
reporting, limited availability of objective data and standardisation in diagnostic 
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criteria. We suggest that the true burden of diabetes in Ireland is underestimated 
(200). In 2010, the National Clinical Programme in Diabetes was established to 
improve and standardise patient care in Ireland (7). Reliable baseline data are needed 
to monitor improvements in care over time at a national level. Therefore, we suggest 
that a comprehensive national diabetes register is urgently needed in Ireland.  
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Figure 3.PRISMA flow chart depicting the selection process of articles included in the 
systematic review 
69 
 
Table 3. Characteristics of studies reporting the prevalence of diabetes among adults in the Republic of Ireland, 1998-2011 
Author Year of 
data 
collection 
Study design National or 
regional 
Setting Population Sampling frame Sampling 
method 
Sample 
size 
Males 
(%) 
Age 
(years) 
Study 
quality  
(out of 9) 
Diabetes prevalence            
Sheily and 
Kelleher 21 
1998 Cross-sectional National  Household General 
population 
Electoral register Multistage 
sample 
1632 47.7 ≥ 55 7 
Creagh et al.22 1998 Cross-sectional Regional 17 GP 
practices 
Primary Care 
Patients 
Practice list Stratified 
random 
1018 48.2 50-69 6 
Census Statistic 
Office (CSO)26 
 2001 Survey National Household General 
population 
Census Total sample 3917203 - ≥18 5 
Sheily and 
Kelleher 21 
2002 Cross-sectional National Household General 
population 
Electoral register Multistage 
sample 
1745 41.7 ≥ 55 7 
Balanda et al.11 2007 Cross-sectional National Household General 
population 
Geodirectory Multistage 
probability 
10,364 49.5 ≥18 8 
Gallagher et al.23 2009-
2010 
Cross-sectional National Database Patients 
covered by 
GMS, LTI, DPS 
schemes 
HSE-PCRS 
pharmacy claims 
data base 
Total sample 
2009 
2010 
 
3493974 
3490877 
 
- 
 
 
≥16 
 
6 
Leahy et al.24 2009-
2011 
Cross-sectional 
analysis of 
longitudinal 
study 
National Household & 
designated 
health centre 
General 
population 
 
Geodirectory Multi-stage 
probability 
5377 46.5 ≥50 8 
O’Connor et al.25 2010-
2011 
Cross-sectional Regional Primary care 
centre 
Patients Practice list Random 2047 49.2 50-69 8 
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Table 4. Characteristics of studies reporting the prevalence of diabetes related complications among adults in the Republic of Ireland, 1998-2011 
Author Year of 
data 
collection 
Study design National or 
regional 
Setting Population Sampling frame Sampling 
method 
Sample 
size 
Males 
(%) 
Age 
(years) 
Study 
quality  
(out of 9) 
Complication prevalence 
Kelliher et al.27 2003 Cross-sectional National  National 
Council for 
Blind Ireland 
(NCBI) 
All person 
registered blind 
NCBI database Total sample 6826 - Adults 8 
Buckley et al.32 2009 Cross-sectional National Population People with 
diabetes 
Hospital In-
Patient Enquiry 
(HIPE) dataset 
Total sample 723551 - ≥20 
years 
9 
Marsden et al.33 2008-
2009 
Audit Regional 20 general 
practices 
Patients with 
T1 & T2 DM 
registered with 
diabetes 
structure care 
programme 
Practice patient 
list 
Every second 
person from 
list 
1071 51.9 63 (sd 
13) 
5 
Hurley et al.28 2008-
2009 
Cross-sectional 
analysis of 
longitudinal 
study 
Regional General 
practices 
with diabetes 
nurse 
Patients with 
T1 & T2 DM 
Practice diabetes 
register 
Researchers 
selected 
eligible 
participants  
563 60 64 (sd 
13.4) 
6 
Farrell & 
Moran29 
2010 Cross-sectional Regional 30 general 
practices 
T2 DM Diabetes 
imitative 
database 
Stratified 
sampling  
309 - - 5 
Tracey et al.30 2009-
2011 
Cross-sectional 
analysis of 
longitudinal 
study 
National Household General 
population 
Geodirectory Multi-stage 
probability 
8175 53 ≥50 8 
McHugh et al.31 2011 Cross-sectional Regional 30 general 
practices 
Patients with 
T1 & T2 DM 
Practice patient 
list 
All persons 
with 
T1&T2DM 
invited 
1542 57.3 65 (sd 
13) 
7 
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Table 5. Prevalence of diabetes among adults in included studies, 1998-2011 
Study Year of 
data 
collection  
Response 
rate (%) 
Sample size Age  Diabetes 
type 
Diagnostic 
criteria 
Estimate Prevalence % (95%CI) 
 Males Females Total 
Sheily and 
Kelleher 21 
1998 62 1632 ≥ 55 years All SR* Diagnosed 6.1 4.3 5.4 
Creagh et al 22 1998 69.1 1018 50-69 years 2  FPG^ Diagnosed 
Undiagnosed 
Total 
Total ≥65 years 
- 
- 
- 
13 
- 
- 
- 
7 
2.8 
1.2 
3.9 (2.9-5.4) 
- 
CSO26 July- Sept. 
2001 
- 3917203 ≥ 18 years All SR Diagnosed ≥18 years 
≥65 years 
 
- 
1.7 
 
- 
1.4 
 
1.5 
4.5 
Sheily and 
Kelleher 21 
2002 53 1745 ≥ 55 years All SR Diagnosed 8.0 5.1 6.4 
Balanda et al.11 
 
 
 
 
 
2007 
 
 
 
 
 
62 
 
 
 
 
 
10,364 
 
 
 
 
 
≥ 18 years 
 
 
 
 
 
All 
 
 
 
 
 
SR or  
medication use 
or HbA1c# 
 
 
Diagnosed    
18 - 44 years 
45+ years 
Total  ≥ 18 years     
Undiagnosed ( ≥ 45 
years) 
Total (diagnosed & 
undiagnosed ≥ 45 years) 
 
- 
6.8 (5.7-7.9) 
- 
4.0 (1.6-6.3) 
 
10.8 (8.2-13.4) 
 
- 
5.4 (4.3-6.6) 
- 
1.7 (0.3-3.0) 
 
7.1 (5.3-8.9) 
 
0.7 (0.5 - 0.9) 
6.1 (5.5-6.9) 
3.5 (3.1-3.9) 
2.8 (1.4-4.1) 
 
8.9 (7.3-10.5) 
Gallagher et al.23 2009 
2010 
- 3493974 
3490877 
≥ 18 years 2 At  least 1 
prescription of 
diabetes 
medication 
Diagnosed 
2009 
2010 
 
- 
- 
 
- 
- 
 
2.8 
3.1 
Leahy et al. 24 2009-2011 62 5377 ≥ 50 years 2 SR or  
medication use 
or HbA1c# 
Diagnosed 
Undiagnosed 
Total (diagnosed & 
undiagnosed) 
50-59 years 
60-69 years 
70-79 years 
80+ years 
- 
- 
11.8 (10.3-13.3)+ 
 
5.1 (4.0-7.0) 
6.0 (5.0-8.0) 
12.0 (8.0-14.0) 
10.0 (5.0-15.0) 
- 
- 
7.3 (6.0-8.5)+ 
 
4.0 ( 
14.0 (11.0-16.0) 
17.0 (14.0-21.0) 
25.0 (15.0-36.0) 
8.6 (7.6-9.5) 
0.9 (0.6-1.1) 
9.5  (8.5-10.4) 
 
5.0 (4.0-6.0) 
- 
- 
16.0 (10.7-21.4) 
 
O Connor et al.25 
 
2010-2011 
 
67.9 
 
2047 
 
50-69 years 
 
2 
 
SR or  
medication use 
or HbA1c# 
 
Diagnosed 
Undiagnosed  
Total  
 
6.8+ 
7.1+ 
11.1+ 
 
3.1+ 
2.7+ 
6.0+ 
 
5.0 (4.1–6.0) 
3.5 (2.8–4.4) 
8.5 (7.4–8.8) 
*SR: self-reported data; ^Fasting plasma glucose (American Diabetes Association criteria (ADA, 1997); # HbA1c (ADA, 2010); +p for difference < 0.05
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Table 6. Prevalence of microvascular and macrovascular complications in included studies, 2003-2011 
Author Year of 
study  
Response rate 
(%) 
Sample 
size 
Age  Diabetes 
type 
Time 
since 
diabetes 
diagnosis 
Data source Diagnostic method Type of complication  Prevalence  
        (%) 
   
          Total 
Kelliher 
et al.27 
2003 - 6826 Adults All - National blind 
registry 
Visual acuity of <6/60  in 
better eye/ visual field 
subtending  angle of 20 
degrees/< less 
Blindness due to diabetic 
retinopathy 
 
4.7 
 
 
Buckley 
et al.32 
2009 - 723, 551 ≥20 years All - Hospital 
discharge data 
ICD-10 codes Non-traumatic lower leg 
amputation  
0.2 
Marsden 
et al. 26 
Nov 2008-
March 
2009 
72 1071 63 years 
(sd 13) 
T1:7.5% 
T2:92.3% 
15 years  Electronic & 
paper clinical 
notes & referral 
letters 
- 
Risk classification score                                    
ACR 2.5-25 
ACR >25 
- 
- 
- 
- 
 
Diabetic retinopathy  
Foot ulcer
Microalbuminuria  
Proteinuria   
Myocardial Infarction 
Heart Failure  
Transient Ischemic Attack  
Stroke  
Total macrovascular 
24.8 
2.5 
32.1 
6.0 
0.4 
0.3 
1.5 
0.5 
3.5 
Hurley et 
al.28 
Feb 2008- 
Sept 2009 
68 563 64 years 
(sd 13.4) 
T1:10% 
T2: 90% 
7.7( 8.2) 
years 
Clinical foot 
examination & 
practice medical 
records 
Scottish Intercollegiate 
Guidelines Network risk 
stratification 
system & previous doctor 
diagnosis 
Documented diabetic neuropathy                   
Foot ulceration 
Past amputation 
Neuropathy symptoms at 
examination  
3.0 
3.7 
1.7 
32 
Farrell & 
Moran29 
2010 - 309 - T2 - Chart review - Diabetic retinopathy 
Neuropathy  
Peripheral vascular disease 
Chronic kidney disease 
Cerebrovascular disease 
6.5 
12.3 
12.9 
5.5 
5.2 
Tracey et 
al.30 
2009-
2011 
62 655 ≥50 years T2 5 (IQR 3-
10) years 
SR previous 
doctor diagnosis  
- Diabetic retinopathy 
Neuropathy 
Leg ulcer 
Nephropathy 
Proteinuria  
Total macrovascular 
8.2 (6-10) 
14.6 (11-18) 
4.2 (2.-6) 
5.1 (3-7) 
6.1(4-8) 
15.1 (12-18) 
McHugh 
et al.31 
2011 GP= 94%; 
Screening 
uptake= 43% 
1542 65 years 
(sd 13) 
T1:4.9% 
T2:85.6% 
- Eye examination 
& clinical records 
Fundus  45° digital PASA-
approved camera 
Background (R1) 
Pre proliferative (R2) 
Proliferative (R3) 
Any diabetic retinopathy  
21.5 (19-23) 
   3.4 (2-4) 
   0.7 (0.4-1.3) 
25.6 (23-27) 
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Figure 4. Forest plot of individual and summary diabetes prevalence estimates of included studies. 
1.Diagnosed diabetes adults aged 18+ years
CSO, 2000
Balanda et al., 2007
Gallaher, 2014
Subtotal  (I^2 = 100.0%, p = 0.00)
2.Diagnosed & undiagnosed diabetes adults aged 45+ years
Creagh et al., 1998
Balanda et al. 2007
Leahy et al. 2015
Connor et al., 2012
Subtotal  (I^2 = 93.2%, p = 0.00)
3. Diagnosed diabetes adults aged 45+ years
Creagh et al., 1998
Sheily & Kelleher, 1998
Sheily & Kelleher, 2002
Balanda et al., 2007
Leahy et al., 2015
Connor et al., 2012
Subtotal  (I^2 = 93.5%, p = 0.00)
4. Undiagnosed diabetes adults aged 45+ years
Creagh et al., 1998
Balanda et al., 2007
Leahy et al. 2015
Connor et al., 2012
Subtotal  (I^2 = 95.1%, p = 0.00)
Study
1.50 (1.49, 1.51)
3.50 (3.16, 3.87)
3.09 (3.07, 3.11)
2.62 (1.41, 4.17)
3.93 (2.82, 5.31)
8.92 (7.33, 10.74)
9.52 (8.75, 10.34)
8.50 (7.33, 9.79)
7.61 (5.49, 10.03)
2.85 (1.92, 4.07)
5.45 (4.40, 6.67)
6.36 (5.26, 7.61)
6.18 (4.85, 7.75)
8.61 (7.87, 9.39)
5.03 (4.13, 6.07)
5.66 (4.13, 7.43)
1.28 (0.68, 2.17)
2.83 (1.94, 3.97)
0.91 (0.67, 1.20)
3.52 (2.76, 4.41)
1.98 (0.81, 3.64)
ES (95% CI)
  
0 1 2 3 4 5 6 7 8 9 10 11 12
74 
 
 
 
Figure 5. Prevalence of self-reported diabetes among adults aged 18 years and over in Ireland, 2004-2015. 
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4.1 Abstract 
Aim: To investigate the prevalence of diagnosed type 2 diabetes and its related 
complications in a nationally representative sample of older adults in the Republic of 
Ireland.    
Research Design and Methods: Cross-sectional analysis of a population-based 
sample of adults aged ≥50 years from the first wave of The Irish Longitudinal Study 
on Ageing (TILDA), (2009-2011). Diagnosed type 2 diabetes prevalence was estimated 
by self-report or use of oral hypoglycemic agents. The prevalence of microvascular 
and macrovascular complications was determined by self-report.  
Results: Diagnosed type 2 diabetes prevalence was 8.4% (95% CI: 7.8%- 9.0%) and 
was higher among men (10.3% [95% CI: 9.4%-11.2%]) than women (6.6% [95% CI: 
5.9%-7.5%]); p ≤ 0.001. Among participants with diagnosed type 2 diabetes, the 
overall prevalence of microvascular complications was 26.0% (95% CI: 22.4%-30.0%) 
with no evidence of gender-specific differences (p= 0.7). The overall prevalence of 
macrovascular complications was 15.1% (95% CI: 12.2%-18.4%) and was higher 
among men (17.8% [95% CI: 14.3%-23.1%]) than women (11.4% [95% CI: 7.7%-16.4]); 
p ≤ 0.001.  
Conclusions: In the absence of a national diabetes register, these findings provide a 
robust estimate of the national prevalence of diagnosed type 2 diabetes and level of 
complications among adults aged 50 years and over in Ireland.  
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4.2 Background 
Over the past number of years, the global prevalence of type 2 diabetes has 
continued to rise (160, 201). Regional data from Ireland showed that the prevalence 
of diagnosed type 2 diabetes among middle aged primary care patients ranged from 
2.8% in 1998 (170) to 5% in 2010-2011 (173). Cross-sectional analysis of a national 
prescription database demonstrated a higher prevalence (9.1%) among adults aged 
over 65 years in 2010 (202). Type 2 diabetes is a significant cause of blindness, non-
traumatic lower limb amputations, end-stage renal disease and CVD (160, 201). The 
Cost of Diabetes in Ireland Study (CODEIRE), based on data from four hospitals in 
1999/2000, found that microvascular complications were evident in 20% of patients 
with type 2 diabetes and macrovascular complications were present in 18% (192). 
Similar to other countries, Ireland does not have a national diabetes register or 
universal data-capture system to monitor the burden of type 2 diabetes and related 
complications. Prevalence estimates rely on data from observational studies (164, 
170, 173, 192, 202, 203). However, these estimates can vary due to differences in 
age ranges, study populations and case finding methods; comparability between 
studies is limited making it difficult to observe trends over time (159).   
Reliable population-based data are necessary so the effectiveness of national 
diabetes strategies can be assessed over time (72, 159). The development of a 
national strategy falls under the remit of the National Clinical Programme in 
Diabetes, which was established in 2010 to improve and standardise care for people 
with diabetes in Ireland (7).  Prior to the implementation of new prevention and 
treatment strategies for diabetes, it is important to quantify the burden of disease in 
the community (159). The aims of this study are to estimate the prevalence of 
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diagnosed type 2 diabetes among adults aged 50 years and over and to determine 
the prevalence of microvascular and macrovascular complications in those with 
diagnosed type 2 diabetes.  
4.3 Methods 
Data from the first wave (2009-2011) of The Irish Longitudinal Study on Ageing 
(TILDA) were utilised to conduct cross-sectional analysis. TILDA is a population-based 
prospective cohort study of community- dwelling adults aged 50 years and over; 
methods have been reported in detail previously (19, 193).   Data collected within 
TILDA include computer-assisted personal interviewing (CAPI) and a health 
assessment. The CAPI was administered by trained social interviewers in participants’ 
homes. Those who completed the CAPI were invited to attend a designated health 
assessment centre or a home-based assessment for a physical examination (19, 193). 
Data collected via the CAPI and during the health assessment were used in analysis.  
Ethical approval was obtained from the Faculty of Health Sciences Research Ethics 
Committee of Trinity College Dublin.  
4.3.1 Classification of diagnosed Type 2 diabetes  
Individuals were classified as having diabetes if they self-reported a previous doctor 
diagnosis or if they reported use of oral hypoglycemic agents (OHA) during the CAPI. 
Anyone aged <40 years at diabetes diagnosis and injecting insulin but not on OHA 
was classified as having Type 1 diabetes. All others who reported a doctor diagnosis 
of diabetes were classified as having type 2 diabetes. 
4.3.2 Classification of macrovascular and microvascular complications  
All participants were asked the question “Has a doctor ever told you that you have 
any of the conditions on this card?”. Heart attack (Myocardial infarction), heart 
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failure (congestive cardiac failure), stroke (Cerebrovascular accident) and mini stroke 
(TIA) were included in the list and were defined as macrovascular complications. 
Participants who reported a doctor diagnosis of diabetes during the CAPI were asked 
the question “Has a doctor ever told you that you have any of the following 
conditions related to your diabetes?”. The conditions listed were: leg ulcer, protein 
in urine (proteinuria), lack of feeling and tingling pain in legs and feet due to nerve 
damage (diabetic neuropathy), damage to the back of your eye (diabetic retinopathy) 
or damage to your kidneys (diabetic nephropathy) and these were defined as 
microvascular complications.  
4.3.3 Statistical analysis  
Analysis was carried out in Stata version 13 for windows (StataCorp, College Station, 
TX) using the survey function (svy). Statistical significance was defined as p < 0.05. 
Comparisons with data from the Quarterly National Household Survey (174) 
demonstrated that individuals with lower levels of educational attainment were 
significantly under-represented in TILDA and there were also significant differences 
in the response rate among particular age and gender groups (19). For instance, 
compared to the QNHS, younger males and older females from the lower educational 
groups were significantly less likely to participate in TILDA. Inverse probability 
weights were calculated to allow for this differential non-response and were applied 
to all analyses to provide population estimates  (19, 193).  
The prevalence of diagnosed type 2 diabetes was calculated as follows: the number 
of TILDA participants classified with diagnosed type 2 diabetes was divided by the 
total TILDA population. The prevalence of macro- and microvascular complications 
were calculated in those with self-reported diagnosed type 2 diabetes. Prevalence 
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was expressed as a percentage with corresponding 95% confidence intervals (95% 
CI). Group-specific differences were analysed using Pearson’s chi-square test for 
categorical data and Student’s t-test for continuous data.  
4.4 Results 
4.4.1 Prevalence of diagnosed type 2 diabetes  
A total of 8175 participants from 6282 households were recruited and completed the 
CAPI (response rate 62%). Overall, 672 individuals had diagnosed diabetes. Of these, 
655 participants were classified as having type 2 diabetes and 17 were classified as 
having Type 1 diabetes. Individuals that self-reported a previous diagnosis of type 2 
diabetes (n=617) did not significantly differ from those categorised as having 
diabetes based on use of oral hypoglycaemic agents (n=38) in terms of age (p= 0.8), 
gender (p= 0.3), educational attainment (p= 0.2) or cognitive function (p= 0.5). 
Physical measurements (Body mass index [BMI], mean waist circumference [WC], 
mean systolic and diastolic blood pressure) were only available for participants who 
attended the health assessment. (n=5864; response rate 72%).   
Baseline characteristics by diagnosed type 2 diabetes status are illustrated in Table 
7. The prevalence of diagnosed type 2 diabetes among TILDA participants aged ≥50 
years was 8.4% (95% CI: 7.8%- 9.0%) and was highest in those aged 75 years and over 
(75+ years: 11.8% [9.9%-13.8%] vs. 65-74 years: 11.1% [9.8%- 12.4] vs. 50-64 years:  
6.3% [5.6%-7.0%]). The prevalence was significantly higher among men (10.3% [95% 
CI: 9.4%-11.2%]) compared to women (6.6% [95% CI: 5.9%-7.5%]; p ≤ 0.001).  
4.4.2 Prevalence of diabetes-related complications  
Among those with diagnosed type 2 diabetes, the overall prevalence of 
macrovascular complications was 15.1% (12.2%-18.4%) and was higher among men 
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(17.8% [14.3%-23.1%]) than women (11.4% [7.7%-16.4]); p ≤ 0.001.  The overall 
prevalence of microvascular complications was 26.0% [22.5%- 29.9%]; with no 
gender-specific differences in prevalence identified (p=0.7). Neuropathy was the 
most commonly reported microvascular complication (14.6% [11.4%-18.2%]) 
followed by retinopathy (8.2% [6.2%-10.9%]), proteinuria (6.1% [4.3%-8.6%]), kidney 
damage (5.1% [3.4%-7.6%]) and leg ulcer (4.2% [2.8%-6.4%]).  
4.5 Discussion 
 
4.5.1 Main findings 
This is the first study of the prevalence of macrovascular and microvascular 
complications among older adults with diagnosed type 2 diabetes using nationally 
representative data from Ireland. Direct comparisons with research in Ireland is 
limited as previous studies focus on specific age groups (170, 173, 202) and/or were 
carried out in a specific region (170, 173, 192) or care setting (170, 173, 192) or used 
different case finding methods (192, 202). O Connor et al. (173) also used self-report 
and the use of OHAs to determine the prevalence of diagnosed type 2 diabetes in 
primary care patients aged 50-69 years. Yet they reported a slightly lower prevalence 
(5%) than in a similar age group in our study (6.3%). Likewise, O’Shea et al. (202) also 
reported a lower national prevalence of diagnosed type 2 diabetes in adults aged 65 
years and over (9.7% vs. 11%). In contrast to our study, their estimates were based 
on patients who were pharmacologically treated for type 2 diabetes and did not 
capture those who managed their diabetes with diet alone (202). Similar to our 
findings, CODEIRE (192) found that among patients with type 2 diabetes from four 
out-patient clinics in Ireland, neuropathy and retinopathy were the most prevalent 
microvascular complications. However, in our study, the prevalence of these 
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conditions was much lower than that reported by CODEIRE (192) (neuropathy: 15% 
vs. 25%; retinopathy: 8.2% vs. 15%). This variation may be explained by differences 
in data collection methods (medical records vs. self-report). 
4.5.2 Strengths and limitations  
The major strength of this study is the large national population-based sample; 
findings from this study provide comprehensive baseline data on the burden of 
diagnosed type 2 diabetes in Ireland. The longitudinal study design of TILDA will 
permit future analysis of trends in the prevalence of diagnosed type 2 diabetes and 
related complications within the older population (72).  
However, several limitations need to be considered when interpreting the findings.  
Misclassification bias may have led to an inaccurate estimation of prevalence as case 
finding methods were based on self-report. When compared to medical records, data 
from self-report have been shown to underestimate the prevalence of diabetic 
retinopathy (195). However, national (173) and international (196-198) studies have 
indicated that compared to medical records, self-report is a suitable method to 
determine type 2 diabetes prevalence. Secondly, our study only included those with 
diagnosed type 2 diabetes and was limited to adults aged 50 years and over; 
therefore our prevalence estimates may underestimate the actual burden of 
diabetes in Ireland. Diabetes-related complications can exist in those with 
undiagnosed diabetes (204, 205). Irish data have demonstrated that the inclusion of 
undiagnosed type 2 diabetes can increase prevalence estimates up to 40% (170, 173, 
203). The younger population in Ireland have lower diabetes prevalence (164); 
therefore prevalence rates of complications are possibly lower in this age group. 
Finally, certain members of the population were under-represented in the TILDA 
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sample; however, weights were calculated to correct for differential non-response, 
minimising the possibility of selection bias (19, 193).  
4.5.3 Conclusions 
Despite these limitations, findings from this study are useful for policy makers 
planning the development of diabetes services in Ireland.  Further research is 
warranted to estimate the national prevalence of undiagnosed type 2 diabetes and 
determine the burden of diabetes-related complications in the younger population.  
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Table 7. Characteristics of the first wave TILDA sample aged 50 years and over, 2009-2011 
 
 General population 
(n=7503)* 
Diagnosed  
type 2 Diabetes 
(n=655) 
 
Variables 
Total 
% (95%   CI) 
Total 
% (95% CI) 
P 
 
Age 
≥ 65 yrs. 
 
40 (38-42) 
 
57 (52- 61) 
 
< 0.001 
Location  
Dublin 
Other city 
Rural  
 
26 (23-30) 
30 (27-34) 
44 (40-47) 
 
28 (23-33) 
32 (27-37) 
40 (35-46) 
 
0.3 
Education 
Primary/none 
Secondary 
Third level/higher  
 
37 (36-39) 
44 (43-45) 
19(18-20) 
 
51 (47-55) 
37 (33-41) 
12 (10- 15) 
 
< 0.001 
Medical cover 
State assisted  
Private insurance 
Dual cover 
No additional cover  
 
35 (33-37) 
38 (36-40) 
16 (15-17) 
11 (10-12) 
 
50 (45- 54) 
24 (20-27) 
19 (16- 23) 
7.0 (5.0-10) 
 
< 0.001 
Smoking 
Never 
Past  
Current  
 
43 (42-44) 
38 (36-38) 
20 (19-21) 
 
36 (32-40) 
46 (41- 50) 
19 (16-22) 
 
< 0.001 
Physical activity  
Low 
Moderate 
High  
 
32 (30-33) 
34 (33-35) 
34 (32-38) 
 
45 (41-50) 
34 (30-38) 
21 (18-25) 
 
< 0.001 
Diagnosed  
Hypertension 
High cholesterol  
 
36 (34-37) 
36 (35-38) 
 
63 (58-67) 
52 (48-56) 
 
< 0.001 
0.4 
Health assessment 
 
General 
population 
(n=5427) 
Diagnosed type 2 
diabetes 
(n=437) 
p 
BMI 
Normal 
Overweight 
Obese  
 
23 (22-25) 
44 (42-45) 
33 (32-34) 
 
7.4 (1-10) 
33 (30-38) 
60 (54- 64) 
 
< 0.001 
 
 
BMI (kg/m2) ǂ 28 (4.5) 31 (5.1) < 0.001 
WC (cm) § 91 (63) 100 (87)  0.02 
Blood pressure 
Systolic (mmHg) 
Diastolic (mmHg) 
 
135 (20) 
83 (11) 
 
139 (20) 
81 (11) 
 
< 0.001 
< 0.001 
Cholesterol 
HDL (mmol/l) 
LDL (mmol/l ) 
 
1.6 (0.4) 
2.9 (0.9) 
 
1.3 (0.3) 
2.2 (0.9) 
 
< 0.001 
< 0.001 
* Excluding 17 based on Type 1 diabetes criteria  
ǂ Mean and standard deviation; provided for continuous variables    
§ Optimal waist circumference: men ≤ 94cm; women ≤80cm 
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5.1 Abstract 
Aim: To explore risk factors for macro-and micro vascular complications in a 
nationally representative sample of adults aged 50 years and over with type 2 
diabetes in Ireland. 
 Methods: Data from the first wave of The Irish Longitudinal Study on Ageing (TILDA), 
(2009-2011) was used in cross-sectional analysis. The presence of doctor diagnosis of 
diabetes, risk factors and macro-and micro vascular complications were determined 
by self-report. Gender-specific differences in risk factor prevalence were assessed 
with the Chi-squared test. Binomial regression analysis was conducted to explore 
independent associations between established risk factors and diabetes related 
complications.  
Results: Among 8175 respondents, 655 were classified as having type 2 diabetes.  
Older age, being male, a history of smoking, a lower level of physical activity and a 
diagnosis of high cholesterol were independent predictors of macrovascular 
complications.  Diabetes diagnosis of 10 or more years, a history of smoking and a 
diagnosis of hypertension were associated with an increased risk of microvascular 
complications. Older age, third level education and a high level of physical activity 
were protective factors (p < 0.05).  
Conclusions: Early intervention to target modifiable risk factors is urgently needed 
to reduce diabetes-related morbidity in the older population in Ireland.  
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5.2 Background 
Over the past two decades, the global burden of diabetes has increased significantly 
(5, 207, 208). Between 1998 and 2015, the prevalence of diabetes increased from 
2.2% to 5.2% among the adult population in Ireland (159). In 2010, diabetes was the 
ninth leading cause of mortality (208) and the 14th largest cause of disability adjusted 
life years (DALYs) (207) worldwide. The economic cost of diabetes is also high and 
will continue to rise; approximately 12% of the world’s total health expenditure was 
spent on diabetes in 2010 (32). The vast majority of this burden is attributable to the 
macrovascular (myocardial infarction, congestive cardiac failure, cerebrovascular 
accident) and microvascular (diabetic neuropathy, retinopathy, and nephropathy) 
complications of diabetes (5). The Cost of Diabetes in Europe - Type II study reported 
that 72% of people had at least one diabetes- related complication (59). In Ireland, 
the prevalence of macro- and micro vascular complications among adults aged 50 
years and over with type 2 diabetes is 15% and 26% respectively (178).  
Compared to the general population, individuals with type 2 diabetes are at an 
increased risk of developing CVD (47, 48). Type 2 diabetes is also a significant cause 
of blindness in adults, non-traumatic lower limb amputations, and end-stage renal 
disease resulting in transplantation and dialysis (5). We reported that the risk of 
visual impairment, in adults aged 50-69 years, is approximately four times higher in 
the population with diabetes compared to those without diabetes (209). Buckley et 
al. (14) found that the risk of an individual with diabetes undergoing lower-leg 
amputation was 22 times that of an individual without diabetes.  
Time-related variables, such as age and longer diabetes duration are associated with 
the onset of diabetes related complications (78). Established risk factors for CVD such 
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as hypertension, high cholesterol and smoking further increase the likelihood of 
developing both macro- and micro vascular complications (86). Socio-economic 
status (SES) has also been identified as a predictor of microvascular complications. 
Lower educational attainment is considered to influence the development of such 
complications through health behaviours, access to care and processes of diabetes 
care (98, 102, 103). While the national prevalence of diagnosed type 2 diabetes and 
related complications has been established among older population in Ireland (178), 
evidence on the individual level risk factors for  macro- and micro- vascular 
complications is lacking. Identification and treatment of risk factors can delay or 
prevent the development of diabetes related complications (5). Therefore, the 
purpose of this paper is to identify the determinants of macro- and micro -vascular 
complications among adults aged 50 years and over with diagnosed type 2 diabetes. 
5.3 Methods 
5.3.1 Data source 
Data from the first wave (2009-2011) of The Irish Longitudinal Study on Ageing 
(TILDA) a population-based prospective cohort study of community- dwelling adults 
aged 50 and over in Ireland were used in this cross-sectional analysis (19). A 
nationally representative sample was selected using the RANSAM sampling 
technique from a listing of all residential addresses in the Republic of Ireland (The 
Irish Geodirectory) (210). A total of 8175 adults aged 50 years and over completed a 
computer-assisted personal interview (CAPI), representing a household response 
rate of 62%. The CAPI was administered by trained social interviewers in participants’ 
homes. This recorded detailed information on health, social, and economic 
circumstances. During the CAPI, participant’s reported their medication use and 
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interviewers noted the correct name from the medication packaging. Medications 
were assigned the WHO Anatomic Therapeutic Chemical (ATC) classification codes 
(168). Ethical approval was obtained from the Faculty of Health Sciences Research 
Ethics Committee of Trinity College Dublin. Written informed consent was provided 
by all respondents before participation (19). 
5.3.2 Type 2 diabetes classification 
Methods to classify diagnosed type 2 diabetes and macro- and micro- vascular 
complications have been reported in detail elsewhere (178). In brief, individuals were 
classified as having diagnosed diabetes if they self-reported a previous doctor 
diagnosis or if they reported the use of insulin or oral hypoglycaemic agents during 
the CAPI. Age at diabetes diagnosis (years) was established by self-report. Anyone 
aged less than 40 years at diagnosis and injecting insulin but not on oral 
hypoglycaemic agents was classified as having type 1 diabetes; all others were 
classified as having diagnosed type 2 diabetes (178).  
5.3.3 Macrovascular and microvascular complications 
 All TILDA participants were asked the question “Has a doctor ever told you that you 
have any of the conditions on this card?” Heart attack (Myocardial infarction), heart 
failure (congestive cardiac failure), stroke (cerebrovascular accident) and mini stroke 
(TIA) were included in the list and were defined as macrovascular complications. 
Participants who reported a doctor diagnosis of diabetes were asked the question 
“Has a doctor ever told you that you have any of the following conditions related to 
your diabetes?” The conditions listed were: leg ulcer, protein in urine (proteinuria), 
lack of feeling and tingling pain in legs and feet due to nerve damage (diabetic 
neuropathy), damage to the back of your eye (diabetic retinopathy) or damage to 
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your kidneys (diabetic nephropathy); these were defined as microvascular 
complications (178). Macro- and micro- vascular complications were collapsed into 
dichotomous variables, to indicate the presence or absence of at least one 
complication. 
5.3.4 Covariates 
Socio-demographic, behavioural and medical history variables were recorded in the 
CAPI including: sex, age (50-64 years, 65-74 years, 75+ years), location of household 
(Capital city [Dublin], other town/ city, rural), educational attainment (primary level 
or none, secondary level, third level or higher), medical care cover (means-tested 
public health insurance scheme for those on low incomes, supplementary private 
health insurance, dual cover [both state-assisted cover and private insurance], no 
additional cover for healthcare). Smoking status was classified as ever smoker 
(current and former smoker) and never smoker (non-smoker). Physical activity (low, 
moderate, high) was self-reported using the short version of the International 
Physical Activity Questionnaire (IPAQ) and categorised using the IPAQ scoring 
protocol (211). Duration of diabetes diagnosis was calculated by subtracting age at 
diagnosis from age (years) at interview and was subsequently categorised (0-4 years, 
5-9 years, ≥ 10 years). The use of diabetes medication (oral hypoglycaemic agents, 
insulin or none) was reclassified as diet alone, oral agents alone, insulin alone, or oral 
agents and insulin. A previous doctor diagnosis of hypertension or high cholesterol 
was ascertained by self-report. 
5.3.5 Statistical analysis 
Analysis was carried out in Stata version 13 for windows (StataCorp, College Station, 
TX) using the survey function (svy). Inverse probability weights were applied to all 
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analyses to provide population estimates. Weights were calculated according to the 
distribution of marital status, educational attainment and geographic location using 
Irish census data from 2006-2010 and to the distribution of age and sex using Irish 
census data from 2011 (193). 
Descriptive statistics were used to summarise characteristics of the population with 
diagnosed type 2 diabetes and were stratified by gender. Gender-specific differences 
in categorical variables were analysed using Pearson’s chi-square test. The mean and 
standard deviation were reported if continuous data conformed to Normality and 
the student t-test was conducted to compare means. If data were skewed, the 
median with associated lower and upper quartile values was reported and the Mann-
Whitney test was utilised. 
Associations between risk factors and diabetes related complications were examined 
using a log-binomial regression. Risk ratios (RR) and 95% CI were generated as a 
measure of association. Risk factors served as independent variables and were 
chosen on the basis of previous literature (74, 78-83, 87-90, 98, 212-215) or if 
significant associations were observed in univariate analysis. A forward block-wise 
entry method was used with independent variables which were entered into the 
regression model in three blocks: 1) sociodemographic variables (age, sex and 
education attainment) and duration of diabetes diagnosis, 2) behavioural factors 
(ever smoked and level of physical activity), 3) medical history variables (diagnosis of 
hypertension, high cholesterol). Collinearity was assessed by the variance inflation 
factor (VIF); a VIF of >10 indicated multicollinearity. Statistical significance was 
defined as p < 0.05. 
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5.4 Results 
Of the 8175 participants in TILDA, 634 participants reported a previous doctor 
diagnosis of diabetes and 38 participants did not report a diagnosis of diabetes but 
were classified as having diabetes by the use of oral hypoglycaemic agents or insulin. 
Of these, 17 people were classified as having type 1 diabetes and were excluded from 
the present analysis. Of the 655 people with type 2 diabetes, 57.7% were male and 
the mean age was 66.6 (SD= 8.8) years. Table 8 shows the characteristics of the 
population with type 2 diabetes, stratified by gender. Approximately half of 
participants were diagnosed with diabetes between the ages of 50-69 years (51.8% 
[47.6% to 55.9%]). The median time since diabetes diagnosis was 5.3 years (IQR 2 to 
11 years). Approximately half the study sample had completed secondary or third 
level education (51.1% [46.9% to 55.4%]). In terms of disease management, 17.5% 
(14.8% to 20.6%) of participants managed type 2 diabetes with diet alone, 74.2% 
(70.6% to 77.5%) reported the use of oral hypoglycaemic agents and 7.5% (5.6% to 
10.0%) reported using both oral hypoglycaemic agents and insulin. The prevalence of 
CVD risk factors was high among participants; 18.8% [15.8% to 22.3%]) of participants 
were current smokers, 62.5% (58.1% to 66.6%) reported a previous doctor diagnosis 
of hypertension and 51.7% (47.5% to 55.9) reported a previous doctor diagnosis of 
high cholesterol. Current smoking was higher among females compared to males 
(20.6% [15.5% to 26.5%] vs. 17.5% [13.9% to 26.5%]) and a higher proportion of 
males reported higher levels of physical activity (27.5% [23.2% to 32.3%] vs. 13.7% 
[9.6% to 19.2%]). Fifteen percent (15.1% [12.3% to 18.4%]) of participants reported 
a previous doctor diagnosis of at least one macrovascular complication and 26% 
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(25.5% to 29.9%) of participants reported a previous doctor diagnosis of at least one 
microvascular complication. 
5.4.1 Factors associated with diabetes related complications 
Table 9 presents the results from the binomial regression analyses, where previous 
diagnosis of at least one macrovascular complication served as the dependant 
variable. The risk of a macrovascular complication was higher among older 
participants and (RR 1.6 [1.1 to 2.5] 65 to 74 years; RR 2.0 [1.2 to 3.2] 75 years or 
over vs. 50 to 64 years). Female participants were less likely to report a previous 
diagnosis of a macrovascular complication relative to males (RR 0.6 [0.4-0.8]).  Finally, 
individuals classified as ever smokers had a 60% increase in the risk of a 
macrovascular complication compared to never smokers (RR 1.6 [1.1 to 2.6]).  
Table 10 presents the results from the binomial regression analyses, with previous 
diagnosis of at least one microvascular complication as the dependant variable.  
There was no evidence to suggest that the risk of microvascular complications was 
different in participants diagnosed less than four years compared to those diagnosed 
between five and nine years (RR 1.1 [0.8 to 1.7]). While participants with type 2 
diabetes for 10 or more years were approximately twice as likely to have reported a 
microvascular complication compared to those who had been diagnosed less than 
four years (RR 1.9 [1.4 to 2.5]). Participants who had ever smoked were almost one 
and a half times more likely to report a doctor diagnosis of a microvascular 
complication relative to never smokers (RR 1.4 [1.1 to 2.0]). While the risk of a 
microvascular complication did not differ between those with a secondary level 
education compared to those with primary level or less (RR 0.9 [0.6 to 1.2]), the risk 
was significantly less in participants with a third level education (RR 0.6 [0.4 to 0.9]) 
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compared to those with primary level or less.  The risk of a microvascular 
complication did not differ between participants who reported a moderate level of 
physical activity compared to those with low level of activity (RR 0.8 [0.6 to 1.1]). 
However, participants in the highest physical activity category were 50% less likely to 
report a microvascular complication (RR 0.5 [0.3-0.8]) compared to participants with 
low level of activity. Participants diagnosed with hypertension were one and a half 
times more likely to have reported a previous diagnosis of at least one microvascular 
complication relative to participant’s who had not reported a previous diagnosis (RR 
1.5 [1.1-2.1]). Collinearity was not found between variables (VIF ≤ 2). 
5.5 Discussion 
 
5.5.1 Main findings 
To our knowledge, this is the first study to identify individual level risk factors 
associated with macrovascular and microvascular complications among people with 
type 2 diabetes in Ireland using nationally representative data. Older age, having ever 
smoked and a previous doctor diagnosis of high cholesterol were independently 
associated with an increased risk of macrovascular complications whereas being 
female and high levels of physical activity demonstrated a protective effect. Longer 
duration since diagnosis, having ever smoked and a previous doctor diagnosis of 
hypertension were associated with an increased risk of microvascular complications 
whereas achieving a third level or higher education level and high levels of physical 
activity demonstrated a protective effect. 
Consistent with existing research (88, 89, 95), established risk factors for CVD (88, 89) 
and being male (88, 95) were found to be independent predictors of at least one 
macrovascular complication. The United Kingdom Prospective Diabetes Study 
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(UKPDS) reported that the risk of myocardial infarction and stroke were higher in 
older participants, smokers and those with high cholesterol (88, 89). Prospective 
studies have also identified hypertension (88-90, 214) as a risk factor for the 
development macrovascular complications among individuals with type 2 diabetes; 
however, our study failed to demonstrate a significant association with this risk 
factor. Our findings are not atypical of existing research in this area; the diversity of 
results has been discussed previously (84, 88, 89, 214) Evidence demonstrating an 
association between duration of diabetes diagnosis and macrovascular complications 
is also equivocal. Some studies are in accordance with our findings (84) whereas 
others have reported the opposite (78, 89). Similar to the present study, Fox et al. 
(84) failed to demonstrate duration of diabetes as an independent predictor of 
combined non-fatal macrovascular events (myocardial infarction, stroke, congestive 
heart failure and angina) (84). While baseline data from the ADVANCE trial (78) 
demonstrated that diabetes duration was an independent predictor of non-fatal 
myocardial infarction and non-fatal stroke among 11,140 individuals with type 2 
diabetes aged 55 years and older. Unlike the previous study (78), we were unable to 
conduct complication-specific analysis due to the small number of reported events.  
Consistent with previous research (78-83), longer duration since diabetes diagnosis 
was independently associated with microvascular complications. Diabetes duration 
reflects total glycaemic control and risk factor exposure over time (85). Likewise, 
both smoking and hypertension have been identified as prominent risk factors in the 
development of neuropathy, retinopathy and nephropathy (75, 79-81, 91, 214, 216). 
Similar to previous findings (79, 83, 98-101), higher educational attainment was 
associated with a lower likelihood of microvascular complications in the present 
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study. Education is a universal indicator of SES and is commonly used in 
cardiovascular epidemiology as it usually remains constant after early childhood and 
is less likely to be influenced by social changes or illness in adulthood (217). Lower 
educational attainment has been associated with poorer disease management, lower 
rates of physical activity, fewer ophthalmologic visits and fewer foot examinations 
(98). Earlier detection by systematic screening can prevent or delay the development 
of diabetes related complications. Reductions in leg amputation rates have been 
achieved in the UK following changes to the structure of foot care for those with 
diabetes (218, 219).  
In the present study, the risk of microvascular complications was lower in 
participants who reported a high level of physical activity compared to the lowest 
physical activity group. This protective effect on microvascular morbidity has been 
highlighted previously (81). High levels of physical activity are beneficial for 
individuals with type 2 diabetes as it is linked with better glucose control (81). Similar 
to the present study, the Health and Retirement Study (HRS) in the USA (215) 
reported that individuals with diabetes related microvascular complications were 
less likely to engage in high levels of physical activity. Janevic et al. (215) suggest that 
the development of diabetes-related complications may cause clinical, practical and 
psychological barriers to engaging with physical activity. Therefore, additional 
support maybe needed to achieve recommended amounts of physical activity in 
those who have developed complications (215).  
5.5.2 Strengths and limitations 
The major strength of this study is the large national population-based sample and 
the high response rate (62%). Inverse probability weights were calculated to take into 
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account the under-representation of individuals with lower levels of education 
attainment and to adjust for the lower response rate in age and sex groupings (168). 
Study weights were applied to all analyses to correct for differential non-response. 
Therefore, selection bias was minimised and the TILDA sample is representative of 
the general Irish population (168).   
However, several limitations need to be considered when interpreting the findings. 
Firstly, data used in the analyses were based on self-report and was not ascertained 
by an objective method. Self-reporting is a recognised limitation in all surveys due to 
potential inaccuracies, recall and reporting bias (194). When compared with medical 
records, data based on self-report have been shown to underestimate the prevalence 
of diabetic retinopathy (195) and heart failure (197). In the present study, the 
prevalence of complications may have been underestimated; as a consequence the 
measure of association may be biased toward the null. However, moderate to high 
levels of agreement, between self-report and medical records, have been 
demonstrated for diabetes (197, 198), myocardial infarction (197), stroke (197, 198) 
and hypertension (197). Data on smoking and physical activity were also based on 
self-report where socially desirable responses are a documented phenomenon (194).  
Secondly, recall bias should be considered. Participants who were recently diagnosed 
with diabetes may remember the age of their diagnosis with greater precision. 
Incorrect reporting may result in differential misclassification and could lead to a 
subsequent decrease in the measure of association if the number of years since 
diabetes diagnosis has been overestimated. Nevertheless, the previously 
documented association between microvascular disease and longer duration since 
diagnosis (78-83) was detected in this study. Finally, a cross-sectional study design 
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does not permit assessment of causality. For instance, it is not possible to infer if a 
high level of physical activity reduces the risk of microvascular complications or 
whether the development of microvascular complications inhibits physical activity 
(215).  
5.5.3 Conclusions 
Despite these limitations, findings from this study are in accordance with other 
research from prospective cohort studies. We demonstrated that macrovascular 
complications were more common in the male population and the probability of 
microvascular complications were reduced in participants with higher educational 
attainment. Additionally, modifiable risk factors were independently associated with 
both macro- and micro vascular complications. While addressing lifestyle factors is a 
key part of preventing complications, delivering adequate services for people with 
diabetes is essential in earlier detection and management of complications. In 2010, 
a national diabetes programme was introduced in Ireland (7).  To date, the 
programme has been instrumental in the roll out of a national retinal screening 
programme, the recruitment of Diabetes Nurse Specialists and development of a 
national foot care model (7). Macrovascular and microvascular complications are 
often preventable; therefore findings from this study are useful for policy makers 
planning the development of other diabetes services, including the diabetes cycle of 
care that has been recently introduced into primary care in Ireland (220). Diabetes 
prevalence is projected to increase; therefore effective prevention strategies are 
urgently needed to reduce the future burden of complications in Ireland. 
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Table 8. Descriptive characteristics of the first wave TILDA sample aged 50 years and over   
with diagnosed type 2 diabetes, 2009-2011 
   Type 2 diabetes (total n= 655) 
Variable 
Male 
n (%) 
Female 
n (%) 
 
p 
Total 
% (95% CI) 
Age 
Years (mean, sd.) 
 
66.6 (9.7) 
 
68.6 (10.4) 
 
 
 
67.4 (10.1) 
Location  
Dublin 
Other city 
Rural  
 
92 (25.5) 
113 (30.0) 
182 (44.5) 
 
77 (31.5) 
84 (34.1) 
105 (35.3) 
 
0.17 
 
27.9 (23.1,33.4) 
31.7 (26.9,36.9) 
40.3 (35.2,45.7) 
Educational attainment 
Primary/none 
Secondary 
Third level/higher  
 
163 (48.6) 
137 (37.1) 
89 (14.3) 
 
116 (54.7) 
103 (36.1) 
47 (9.2) 
 
0.12 
 
 
 
51.1 (46.9, 55.4) 
36.7 (32.9, 40.7) 
12.2 (10.1, 14.6) 
Medical cover 
State assisted  
Private insurance 
Dual cover 
No additional cover  
 
163 (43.9) 
111 (27.6) 
86 (19.9) 
30 (8.5) 
 
139 (57.8) 
60 (17.9) 
51 (18.7) 
16 (5.6) 
 
<0.01 
 
49.7 (45.4, 53.9) 
23.6 (20.3, 27.2) 
19.4 (16.2, 23.0) 
7.3 (5.3, 10.1) 
Smoking 
Never 
Past  
Current  
 
114 (29.9) 
210 (52.7) 
66 (17.5) 
 
120 (44.0) 
94 (35.4) 
52 (20.1) 
 
<0.001 
 
35.8 (31.8, 39.9) 
45.5 (41.2, 49.9) 
18.8 (15.8, 22.3) 
Physical activity  
Low 
Moderate 
High  
 
140 (36.8) 
137 (35.7) 
109 (27.5) 
 
143 (56.5) 
77 (29.8) 
43 (13.7) 
 
<0.001 
 
45.0 (40.8,49.2) 
33.3 (29.5,37.2) 
21.8 (18.5,25.5) 
Age of diagnosis  
< 50 years 
50-69 years 
70+ years 
 
54 (16.4) 
196 (55.9) 
112 (27.7) 
 
47 (16.8) 
125 (46.2) 
84 (36.9) 
 
0.04 
 
16.6 (13.7,19.8) 
51.8 (47.6,55.9) 
31.6 (27.8,35.7) 
Duration of DM diagnosis 
Years (median, IQR) 
 
5.0 (1.5,12)  
 
5.5 (2.5,15)  
 
0.5 
 
5.3 (2,11) 
DM treatment 
Diet 
Oral meds 
Insulin 
Both  
Other medication  
Hypertension 
High Cholesterol 
Flu shot 
 
64 (16.7) 
293 (74.7) 
2 (1.0) 
31 (8.2) 
 
221 (58.4) 
164 (43.4) 
286 (74.3) 
 
53 (18.3) 
190 (73.9) 
4 (0.8) 
19 (6.5) 
 
161 (60.0) 
130 (46.5) 
212 (78.5) 
 
0.9 
 
 
 
 
0.6 
0.4 
0.2 
 
17.5 (14.8,20.6) 
74.2 (70.6,77.5) 
0.8 (0.3,1.8) 
7.5 (5.6,10.0) 
 
59.1 (55.4,63.9) 
44.7 (40.4,48.7) 
76.1 (72.4,79.5) 
Doctor diagnosed  
Hypertension 
High cholesterol  
 
236 (61.2) 
192 (50.0) 
 
170 (63.8) 
149 (54.2) 
 
0.9 
0.9 
 
62.5 (58.1, 66.6) 
51.7 (47.5, 55.9) 
DM complications 
Macro 
Micro  
 
73 (17.8) 
89 (25.2) 
 
28 (11.4) 
67 (26.8) 
 
0.04 
0.7 
 
 15.1 (12.3, 18.4) 
26.0 (22.5, 29.9) 
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Table 9. Multivariate binomial regression models exploring independent associations between predictor variables and macrovascular 
complications* 
Predictor 
Model 1† 
RR (95% CI)        p 
Model 2 ǂ 
RR (95% CI)             p 
Model 3§ 
RR (95% CI)          p 
Age  
50-64 years  
65-74 years 
75+ years 
 
1 
1.6 (1.0, 2.5)          0.05 
2.0 (1.3,3.3)         0.003 
 
1 
1.5 (0.9, 2.4)          0.07 
1.8 (1.1, 4.1)          0.01 
 
1 
1.6 (1.1, 2.5)       0.04 
2.0  (1.2, 3.2)     0.005 
Gender 
Male 
Female 
 
1 
0.6 (04, 0.9)        0.007 
 
1 
0.6 (0.4, 0.9)           0.009 
 
1 
0.6 (0.4,0.8)         0.005 
Education 
Primary/less 
Secondary 
Third/higher 
 
1 
0.9 (0.6, 1.3)          0.5 
1.1 (0.7, 1.7)          0.7 
 
1 
0.9 (0.6, 1.4)           0.5 
1.2  (0.7, 1.8)          0.5 
 
1 
0.9 (0.6, 1.3)          0.6 
1.1 (0.7, 1.7)          0.7 
Duration of diagnosis 
0-4 years 
5-9 years 
10 + years 
 
1 
1.0 (0.6, 1.7)         0.9 
1.2 (0.8, 1.8)         0.4 
 
1 
0.9 (0.6, 1.6)          0.9 
1.1 (0.7, 1.6)          0.7 
 
1 
1.0 (0.6, 1.7)        0.9 
1.1 (0.8, 1.7)        0.5 
Ever smoked 
No 
Yes 
  
1 
1.7  (1.1, 2.7)        0.02 
 
1 
1.6 (1.1, 2.6)      0.04 
Physical activity  
Low 
Medium 
High 
  
1 
0.8 (0.6, 1.2)           0.3 
0.5 (0.3, 0.9)           0.01 
 
1 
0.9 (0.6, 1.2)        0.5 
0.5 (0.3, 0.9)        0.03 
Previous hypertension 
No 
Yes 
  
 
 
1 
1.1 (0.8, 1.7)        0.5 
Previous high cholesterol 
No  
Yes 
  
 
 
1 
1.7 (1.1, 2.5)        0.008 
*  Indicating report of at least one macrovascular complication  (heart attack, congestive heart failure, stroke or TIA)                                                                                                                                                                                                                                            
† Variables entered in Model 1: age, sex, education, years since diagnosis                                                                                      
ǂ Variables entered in Model 2: age, sex, education, years since diagnosis, smoking status, physical activity                                                                                                                                
§ Variables entered in Model 3: age, sex, education, years since diagnosis, smoking status, physical activity, doctor diagnosed hypertension, doctor diagnosed high cholesterol 
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Table 10. Multivariate binomial regression models exploring independent associations between predictor variables and microvascular 
complications* 
Predictor  
Model 1† 
RR (95% CI)             p 
Model 2ǂ 
RR (95% CI)             p 
Model 3§ 
RR (95% CI)          p 
Age  
50-64 years 
65-74 years 
75+ years 
 
1 
0.8  (0.6, 1.2)            0.4 
0.7  (0.5, 1.1)            0.1 
 
1 
0.9  (0.7, 1.2)            0.4 
0.7  (0.5, 0.9)           0.02      
 
1 
0.9 (0.7, 1.1)          0.3 
0.6  (0.5, 0.9)         0.01 
Gender 
Male 
Female 
 
1 
1.0  (0.8, 1.4)            0.9 
 
1 
1.1 (0.7, 1.3)            0.8 
 
1 
1.0 (0.8, 1.3)           0.9 
Education 
Primary/less 
Secondary 
Third/higher 
 
1 
0.9 (0.7, 1.2)             0.4 
0.6 (0.4, 0.8)           0.007 
 
1 
0.9 (0.7, 1.2)            0.5 
0.5 (0.4, 0.9)            0.02 
 
1 
0.9 (0.7, 1.2)          0.5 
0.6 (0.4, 0.9)          0.02 
Duration of diagnosis 
0-4 years 
5-9 years 
10+  years 
 
1 
1.2 (0.8, 1.8)           0.3 
2.0 (1.5, 2.7)         0.000 
 
1 
1.1 (0.8, 1.6)          0.5 
1.8 (1.4, 2.5)         0.000 
 
1 
1.1 (0.8, 1.7)         0.5 
1.9 (1.4, 2.5)        0.000 
Ever smoked 
No 
Yes 
  
1 
1.4 (1.1, 2.0)           0.03 
 
1 
1.4 (1.1, 2.0)           0.02 
Physical activity  
Low 
Medium 
High 
  
1 
0.7 (0.6, 1.0)           0.1 
0.5 (0.3, 0.7)         0.001 
 
1 
0.8 (0.6, 1.1)           0.1 
0.5 (0.3, 0.8)       0.003 
Hypertension 
No 
Yes 
  
 
 
1 
1.5 (1.1, 2.1)        0.006 
High cholesterol 
No  
Yes 
  
 
 
1 
1.0 (0.8, 1.3)        0.9 
* Indicating report of at least one microvascular complication (leg ulcer, protein in urine, neuropathy, retinopathy or damage to kidneys)     
 † Variables entered in Model 1: age, sex, education, years since diagnosis                                                                                    
 ǂ Variables entered in Model 2: age, sex, education, years since diagnosis, smoking status, physical activity                                                                                                                              
§ Variables entered in Model 3: age, sex, education, years since diagnosis, smoking status, physical activity, doctor diagnosed hypertension, doctor diagnosed high cholesterol
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6.1 Abstract  
Aim: To describe trends in the incidence of visual impairment and blindness due to 
diabetic retinopathy among adults aged 18-69 years in Ireland between 2004 and 
2013.  
Methods: Data on visual impairment due to diabetic retinopathy in adults aged 18-
69 years or over who are registered with the National Council for the Blind of Ireland, 
(2004-2013) were analysed. Annual incidence rates were calculated for the adult 
population and the population with diagnosed diabetes. Poisson regression was used 
to test for changes in rates over time. The relative, attributable and population risk 
of blindness and visual impairment due to diabetic retinopathy were calculated for 
2013.  
Results: Over the decade, the prevalence of diagnosed diabetes increased from 2.1% 
to 3.6%. Among people with diagnosed diabetes, the incidence of visual impairment 
due to diabetic retinopathy increased from 6.4 (95% CI 2.4-13.9) per 100,000 in 2004 
to 11.7 (95% CI 5.9-21.0) per 100,000 in 2013. The incidence of blindness due to 
diabetic retinopathy varied from 31.9 per 100,000 (95% CI 21.6-45.7) in 2004 to 14.9 
per 100,000 (95% CI 8.2-25.1) in 2013.  
Conclusions: Our findings indicate the need for increased attention to preventive 
measures for microvascular complications among adults with diabetes in Ireland. 
Retinopathy screening has been standardised in Ireland, these findings provide 
useful baseline statistics to monitor the impact of this population-based screening 
programme. 
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6.2 Background 
Vision impairment is a major public health problem worldwide (222). In 2010, it was 
estimated that 0.5% of the global population were blind (222).  In Ireland, the 
prevalence of blindness increased from 0.2% in 2003 (175) to 0.3% in 2010 (223). 
Worldwide approximately 80% of visual impairment cases can be prevented or cured 
(224). In order to reduce the global burden of visual impairment, nine preventable 
causes of visual impairment have been prioritised on the global public health agenda 
including diabetic retinopathy (224). Compared to the general population, individuals 
with diabetes are at an increased risk of losing their eyesight (5). Genz et al. found 
that the risk of blindness in an individual with diabetes was 2.4 times that of an 
individual without diabetes (53).  In Ireland there is no diabetes register or national 
data-capture system to observe diabetes trends in diabetes incidence or prevalence 
over time.  However, findings from a recent systematic review (159) suggest that the 
prevalence of diagnosed diabetes increased from 2.2% in 1998 to 5.2% in 2015. The 
review was unable to distinguish between the various types of diabetes (159); 
however it can be assumed that type 2 diabetes is driving the increase in prevalence 
as it accounts for 90 % of all diabetes cases (2). As the prevalence of diabetes rises, 
visual impairment due to diabetic retinopathy represents a growing global public 
health challenge (73).  
Diabetic retinopathy is a leading cause of preventable vision loss in countries such as 
the UK (225) and the USA (226). In Ireland, it was the second most common cause of 
blindness among adults aged 16-64 years in 2003, with an incidence rate of 0.7 per 
100 000 adults (175). Retinitis pigmentosa was the most common cause of blindness 
among adults aged 16-64 years in 2003; with an incidence rate of 0.9 per 100 000 
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adults (175). The individual and societal costs of visual impairment due to diabetic 
retinopathy are significant (50, 227), and include increased healthcare costs (228, 
229), loss of productivity (229), and severe reduction in healthy life years (230) and 
quality of life (231).  
It is now widely accepted that systematic screening for diabetic retinopathy has the 
potential to reduce the incidence of sight-threatening visual impairment (232). A 
reduction of rates of blindness due to diabetic retinopathy have been noted in 
countries that have established population-based retinal screening programmes as 
part of their national diabetes strategy (53, 66, 67, 233-235).Up until recently, there 
was no national population-based screening programme for diabetic retinopathy in 
Ireland; screening was delivered on a limited basis by local services using different 
models of service provision (236). In 2013, a national retinal screening programme 
(Diabetic Retinascreen) was introduced in Ireland (122) with the objective of reducing 
blindness by 40% through the implementation of a standardised screening and 
treatment service (7). The service was introduced on a phased basis, patient 
registration began in 2013 and full implementation was achieved in late 2014.  
In 2010, the WHO highlighted the importance of within-country data on visual 
impairment to facilitate global efforts aimed at monitoring and eliminating avoidable 
blindness (224). Given that the national programme has only been recently 
introduced, there is limited national data on rates of visual impairment due to 
diabetic retinopathy in Ireland (159). Therefore, this study used national blind 
registry data to establish current rates of visual impairment and blindness due to 
diabetic retinopathy. Data from blind registers allow the absolute burden of visual 
impairment attributed to diabetic retinopathy to be quantified (237). In Ireland, blind 
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registry data have been previously used to describe trends in all-causes of blindness 
in 1996 (238) and 2003 (175). The aims of this study were to 1) estimate the incidence 
of visual impairment and blindness due to diabetic retinopathy among (a) the total 
adult population and (b) population with diagnosed diabetes in Ireland over a ten 
year period (2004-2013); 2) explore whether these rates have changed over time and 
3) estimate the relative, attributable and population attributable risk of visual 
impairment and blindness due to diabetic retinopathy in Ireland in 2013.  
6.3 Methods 
6.3.1 Data source 
Data from the National Council for the Blind of Ireland (NCBI) were analysed. The 
NCBI is a charitable organisation which provides support and services to people 
experiencing sight loss (20). Anyone who is having significant difficulty with their 
eyesight can be referred to the NCBI by a health care professional or family member; 
self-referral is also possible (20). Once referred, the individual’s information is added 
to the NCBI database; however, an ophthalmic assessment report (OAR), to confirm 
the level of visual impairment, is necessary to officially register with the service (20). 
Registration with the NCBI is not compulsory, however those who register can access 
a range of NCBI support services and registration is also required to qualify for the 
state-provided Blind Welfare Allowance (239). The NCBI registry comprises data on 
approximately 15 causes of visual impairment and blindness, including macular 
degeneration, glaucoma, cataract, optic atrophy, retinitis pigmentosa and diabetic 
retinopathy (175, 223). Information such as service-user demographics (gender and 
date of birth), date of registration, visual acuity score and cause of visual impairment 
are recorded on a centralised national database. Information on type of diabetes, the 
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stage of diabetic retinopathy, or risk factors for diabetic retinopathy are not 
recorded. In this study, anonymised data on visual impairment due to diabetic 
retinopathy in adults aged 18-69 years, (January 2004-December 2013) were 
obtained for analysis. 
6.3.2 Numerator data 
The number of new cases of visual impairment due to diabetic retinopathy was 
extracted from the NCBI database for each calendar year. The number of new cases 
due to all other causes of visual impairment was extracted for 2013. Cases were 
excluded if visual acuity score was not recorded. In Ireland, visual impairment is 
categorised into three levels: mild visual impairment (visual acuity between 6/12 and 
6/18 inclusive), moderate visual impairment (best-corrected acuity of less than 6/18 
but better than or equal to 6/60 in the better-seeing eye) and blindness (visual acuity 
of 6/60 or less in the better eye or a visual field restricted to 20 degrees or less) (240). 
These criteria are commonly used in North America, Australia, and most of Europe 
(240). For the purpose of this study, individuals who met the national criteria for mild 
and moderate visual impairment were defined as ‘visual impairment’ and those who 
met the criteria for blindness were defined as ‘blind’.  
6.3.3 Denominator data 
Annual population estimates were obtained from the Central Statistics Office (CSO), 
Ireland (241). A census took place in Ireland in 2006 and 2011; data for other study 
years were CSO inter-censal estimates (241). A diabetes register does not exist in 
Ireland, therefore rates for diagnosed diabetes was taken from model estimates; 
methods have been described in detail previously (159). In brief, using data from four 
nationally representative population-based studies , multivariate Poisson regression 
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models were undertaken to impute annual gender and age-specific (18–29 years, 30-
39 years, 40-49 years, 50-59 years, 60-69 years) rates of diagnosed diabetes. These 
gender and age-specific rates were applied to 2004–2013 population data so the 
absolute number of diabetes cases could be obtained. For the purpose of this study, 
the absolute number of diabetes cases was categorised into two age groups (18-49 
years, 50-69 years). The population without diagnosed diabetes was calculated by 
subtracting the estimated population with diabetes in 2013 from the total population 
in 2013.  
6.3.4 Incidence calculations 
The incidence of visual impairment and blindness due to diabetic retinopathy in the 
total population and the population with diagnosed diabetes was calculated for each 
year 2004–2013; using data from the NCBI as the numerator and the census and 
estimated diabetes population as the denominator for the total population and 
diagnosed diabetes populations respectively. The incidence of visual impairment and 
blindness due to all other causes in the population without diagnosed diabetes was 
calculated for 2013; using data from the NCBI as the numerator and the estimated 
population without diabetes as the denominator. Rates were expressed per 100, 000 
population.  
6.3.5 Statistical analysis 
Age-standardised rates in the total population and the population at risk (in 10-year 
age groups) were calculated using the direct standardisation method, based on the 
age distribution of the last census in Ireland (2011) and the estimated population 
with diagnosed diabetes in 2011, respectively; 95% confidence intervals (95% CI) 
were based on the Poisson distribution. Mean incidence figures, with standard 
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deviations (SD) and 95% CI’s, were calculated for the decade. The risk of visual 
impairment increases with age (63); therefore analysis was stratified by two arbitrary 
age groups (18-49 years, 50-69 years). Poisson regression models, using extra Poisson 
variation, were undertaken to explore variations in rates over time and to examine 
departures from linearity between 2004 and 2013. Sensitivity analysis, comparing 
rates in the total population between census year (2006 and 2011) was also carried 
out.  The number of cases served as the dependant variable, year of registration 
served as the continuous independent variable and population was entered as the 
exposure variable. If this model indicated significant changes in the incident rate ratio 
(IRR) over time (pchange), the likelihood ratio test was undertaken to assess linearity. 
A model including year of registration as a categorical variable was compared to the 
model with year as registration as a continuous variable.  Linearity was determined 
by an insignificant likelihood ratio test (ptrend). The IRR with corresponding 95% CI 
were reported if linearity was established. A two-sided p<0.05 was considered 
statistically significant. 
Age-specific relative risks of blindness and visual impairment (diabetes vs. no 
diabetes) in 2013 were calculated by dividing the rates in the estimated population 
with diabetes by the rates in the population without diabetes. The attributable risk 
(AR) [incidence exposed –incidence unexposed], attributable risk percent (AR %) [AR/ 
incidence exposed *100], population attributable risk (PAR) [incidence population –
incidence unexposed] and the population attributable risk percent (PAR %) [PAR/ 
incidence population * 100] were also calculated. The AR measures the excess risk 
attributed to diabetes, using the difference between the risk in individuals with 
diagnosed diabetes (exposed) and that in individuals without diabetes (unexposed). 
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The PAR measures the excess risk between the risk in the total population in the total 
population and that in individuals without diagnosed diabetes (unexposed). Analysis 
was carried out in Stata 13. 
6.4 Results 
A total of 357 new cases of diabetic retinopathy were registered with the NCBI during 
the 10 year period; 16 cases (5%) were excluded as an OAR had not been returned to 
the NCBI, therefore the level of visual impairment could not be determined. The 
distribution of these cases over the study period is shown in Supplementary file 1 
(Appendix 4). Therefore, 341 new cases were available for inclusion in the current 
analysis. Between 2004 and 2013, a total of 86 cases were newly registered as visually 
impaired (Appendix 4; supplementary file 2); of these 67% were male and the median 
age was 62 years (IQR 57-66). The highest proportion of new cases of visual 
impairment also occurred in those aged 50-59 years (50-69 years: 73 vs. 18-49 years: 
13). A total of 255 patients were newly registered as blind (Appendix 4; 
Supplementary file 3); of these, 58% were male and the median age of registration 
was 59 years (IQR 51-65). The highest number of new blind cases occurred in those 
aged 50-69 years (50-69 years: 195 vs. 18-49 years: 60).  During 2013, 207 people (87 
visually impaired and 120 blind), were newly registered on the NCBI database due to 
all other causes.  
Over the ten year period, the prevalence of diagnosed diabetes increased from 2.1 
% (95% CI: 2.0-2.2) in 2004 to 3.6% (95% CI: 3.5-3.7) in 2013; (ptrend= <0.001). Table 
11 shows the number of new cases for each year, the total adult population, the 
estimated adult population with diabetes, the standardised incidence of visual 
impairment and blindness attributed to diabetic retinopathy. Between 2004 and 
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2013, the mean annual incidence of visual impairment due to diabetic retinopathy 
was 0.3 per 100,000 population (SD: 0.09; 95% CI: 0.2-0.4) and 10.7 per 100,000 
population with diagnosed diabetes (SD: 2.9; 95% CI: 8.6-12.7). During the same time 
period, the mean annual incidence of blindness due to diabetic retinopathy was 0.9 
per 100,000 adults (SD: 0.24; 95% CI: 0.7-1.04) and was 33.2 per 100,000 population 
with diagnosed diabetes (SD: 10.2; 95% CI: 25.9-40.5).  
6.4.1 Trends in the incidence of visual impairment and blindness due to diabetic 
retinopathy 
Over a decade, the incidence of visual impairment due to diabetic retinopathy 
increased in both the total population (IRR: 1.08 [95% CI: 1.01-1.16]; ptrend=0.93) and 
the population with diagnosed diabetes (IRR: 1.05 [95% CI: 1.02-1.1]; ptrend= 0.79). In 
contrast, the incidence of blindness due to diabetic retinopathy in the total 
population did not significantly change during the study period (pchange= 0.73). Over 
the 10 year period, the annual incidence in the population with diabetes did vary 
between years (pchange=0.01); however, there was no evidence of a linear trend (ptrend 
<0.01).  
6.4.2 Age-specific trends in the incidence of visual impairment and blindness 
due to diabetic retinopathy 
Figure 6b illustrates the age-specific trends of visual impairment between 2004 and 
2013. Among adults aged 18-49 years, the incidence remained steady in the total 
population (2004: 0.05 [95% CI 0.001-0.3] to 2013: 0.04 [95% CI 0.001-0.4] per 
100,000; pchange = 0.56), whereas among people with diabetes, the incidence ranged 
from 5.4 (95% CI 0.1-30.0) in 2004 to 2.3 (95% CI 0.05-12.8) per 100,000 in 2013 but 
did not significantly change overtime (pchange = 0.83). In contrast, among adults aged 
50-69 years, the incidence increased in both the total population (2004: 0.3 [95% CI 
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0.08-1.2] to 2013: 1.3 [95% CI 0.6-2.2]; [IRR: 1.09 [1.05-1.13]; ptrend = 0.92) and the 
population with diabetes (2004: 7.6 [95% CI 15.8-22.5] to 2013: 18.1 [95% CI 9.4-
31.6]); [IRR: 1.05 [95% CI: 1.02-1.09]; ptrend = 0.92).  
Figure 6c illustrates age-specific trends of blindness due to diabetic retinopathy 
between 2004 and 2013. Among adults aged 18-49 years, the incidence remained 
stable in the total population (2004: 0.2 [95% CI 0.08-0.5] to 2013: 0.2 [95% CI 0.07-
0.6] per 100,000; pchange = 0.56). However, among people with diabetes, the incidence 
ranged from 26.9 (95% CI 8.7-62.8) per 100,000 in 2004 to 11.5 (95% CI 3.7-26.8) per 
100,000 in 2013 but did not significantly change overtime (pchange = 0.45). Among 
adults aged 50-69 years, the incidence also remained stable in the total population 
(2004: 1.7 [95% CI 0.9-2.9] to 2013: 1.2 [95% CI 0.5-2.1] per 100,000; pchange = 0.15). 
While among people with diabetes, the incidence varied from 33.3 (95% CI 17.7-56.9) 
in 2004 to 16.6 (95% CI 8.3-29.7) per 100, 000 in 2013 (pchange = 0.03); however, there 
was no evidence of a linear trend (ptrend <0.01).  
6.4.3 Sensitivity analysis: trends in the total population between census years 
(2006-2011) 
The results from the sensitivity analysis demonstrated that the incidence of visual 
impairment (pchange= 0.31) or blindness (pchange= 0.59) due to diabetic retinopathy in 
the total population did not significantly change between 2006 and 2011. Among 
adults aged 18-49 years, the incidence of visual impairment and blindness remained 
stable (visual impairment: 2006: 0.05 [95% CI 0.08-0.5] to 2011: 0.09 [95% CI 0.07-
0.6] per 100,000; pchange = 0.98; blindness: 2006: 0.3 [95% CI 0.08-0.5] to 2011: 0.3 
[95% CI 0.07-0.6] per 100,000; pchange = 0.37).  Among adults aged 50-69 years, the 
incidence of visual impairment ranged from 0.6 (95% CI 17.7-56.9) in 2006 to 1.0 
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(95% CI 8.3-29.7) per 100, 000 in 2011 but did not significantly change over time 
(pchange = 0.37). While, the incidence of blindness remained stable (2006: 2.6 [95% CI 
0.08-0.5] to 2011: 2.4 [95% CI 0.07-0.6] per 100,000; pchange = 0.51).  
6.4.4 Relative risk, attributable and population attributable risk of visual 
impairment and blindness in 2013 
The relative risk, attributable and population attributable risk of visual impairment 
and blindness in 2013 are shown in Table 12. In adults aged 18-49 years, the risk of 
blindness was 5.6 times higher in the population with diabetes compared to those 
without diabetes. In 2013, 9% of the risk of blindness in the entire population was 
attributable to diabetes. In adults aged 50-69 years, the risk of visual impairment was 
3.9 times higher in the population with diabetes compared to those without 
diabetes. Sixteen per cent of the risk of visual impairment in the entire population 
was attributable to diabetes in 2013. 
6.5 Discussion 
 
6.5.1 Main findings 
To our knowledge, this is the first study to describe national rates of registered 
blindness and visual impairment due to diabetic retinopathy among the population 
with diagnosed diabetes in Ireland. We observed a change in the incidence of 
blindness due to diabetic retinopathy among people with diabetes over the study 
period, however there was insufficient evidence to confirm a downward trend. This 
is in accordance with previous research describing national trends in the incidence of 
lower leg amputations between 2005 and 2009 among the population with diabetes 
(14). Findings from the present study are in contrast to international research where 
a decrease in the incidence of blindness (53, 67, 69, 225, 234, 235, 242, 243) and 
other diabetes related complications (72) has been documented. It has been 
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suggested that while the rates of some diabetes complications has decreased, the 
absolute number of cases will continue to rise because of the rising prevalence of 
diabetes (72). In the present study, we observed an increase in the prevalence of 
diagnosed diabetes; longer duration of diabetes diagnosis is an established risk factor 
for diabetic retinopathy (73). After 20 years of diabetes, nearly all individuals with 
type 1 diabetes and more than two-thirds of individuals with type 2 diabetes will 
develop some degree of retinopathy (50). Therefore it is possible that the full impact 
of the diabetes epidemic has not yet been realised in Ireland. In contrast, an increase 
in visual impairment was evident in the total population and among people with 
diabetes. 
Comparison with other countries is limited due to differences in visual impairment 
criteria, differing age ranges and varying methods used to estimate the population at 
risk. In the UK, from 2000 to 2009, Hall et al. (234) described a decrease in the 
incidence of blindness attributable diabetes from 1.43 to 1.10 per 100,000 total 
population, and 59.7 to 23.9 per 100,000 population with diagnosed diabetes. 
However, unlike the present study, these rates included adults over 70 years rather 
than being restricted to adults aged 18-69 years. Elsewhere in the UK, between 2001 
and 2005, the mean annual incidence of blindness due to diabetic retinopathy among 
adults aged 16-64 years with diabetes was 22 per 100,000 population (233). This 
estimate is lower than our mean annual estimate (33 per 100,000); however the 
sample in our study was older on average (59 years vs. 55 years) which could lead to 
a higher rate of blindness (63). In the USA, The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy, reported a decline in the incidence of severe visual impairment 
over a 25 year period among those with type 1 diabetes (244). 
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Decreasing trends of blindness and visual impairment due to diabetic retinopathy 
have been attributed to a combination of factors, including improvements in disease 
management and risk factor control, earlier detection and treatment of diabetic 
retinopathy through the implementation of standardised retinopathy screening 
programmes (66, 70). In Ireland, data on risk factors for diabetic retinopathy are not 
routinely collated at a population-level, therefore we were unable to quantify trends 
in mean Hba1c levels or mean blood pressure during the study period. Prior to the 
introduction of the national diabetic retinal screening programme, there was wide 
variation in the delivery of diabetic retinopathy screening in Ireland (236). Regional 
screening initiatives may have contributed to the changing incidence of visual 
impairment and blindness observed in the present study. We found that the 
incidence of visual impairment due to diabetic retinopathy almost doubled over a ten 
year period; this may be indicative of local efforts to screen for diabetic retinopathy. 
The initial introduction of a screening programme results in the detection of more 
diabetic retinopathy cases (66). Countries that have introduced population-based 
retinal screening programmes have observed a decline in the frequency (66) and 
treatment (70) of sight-threatening diabetic retinopathy over time. The national 
programme was fully implemented in 2014; we hypothesize that initially, the 
increasing trend in visual impairment due to diabetic retinopathy will continue and 
will gradually decline post-implementation.  
6.5.2 Strengths and limitations 
The strengths of our study include the analysis of a national centralised database that 
has been previously used in Ireland to describe rates of all-causes of blindness in 1996 
(238) and 2003 (175). To our knowledge, rates of blindness due to diabetic 
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retinopathy have not been estimated since 2003. Furthermore, the risk of visual 
impairment attributable to diabetes has not been previously reported within the Irish 
population.  
However, our study has some limitations that must be considered. Firstly, 
implications of using blind registry data to describe rates in visual impairment and 
blindness have been discussed elsewhere (175, 234, 245). It has been suggested that 
blind registry data may be incomplete, leading to an underestimation the true 
burden of blindness. For example, data from the UK (246) have demonstrated that 
partially sighted individuals are less likely to be registered than blind patients. In 
Ireland, both visually impaired and blind individuals can avail of the services provided 
by the NCBI (20). However, selection bias due to an underreporting of visual 
impairment cases maybe possible as, unlike blindness, registration to the NCBI is not 
financially incentivised (239). Referral to the NCBI also may depend on severity of 
visual impairment further increasing the possibility of self-selection. Therefore, in the 
present study the annual incidence of visual impairment may be underestimated.  
Previous studies have shown that 21-50% (175, 245, 246) of patients are not listed 
on blind registers; furthermore, partially sighted individuals are less likely to be 
registered than blind patients (246). Non-registration has been associated with 
temporary and treatable causes of blindness (175, 246); however, blindness due to 
diabetic retinopathy is irreversible and there is no evidence to suggest that under-
registration is more likely in those with diabetes. It is also recognised that blind 
registry data is only a surrogate measure of incident blindness (234, 246), where 
changes in rates may reflect reporting differences over time rather than true changes 
in disease incidence. In the present study, it is possible that the NBCI may have 
117 
 
become a better known resource over time thereby impacting registration to the 
service. For instance, our findings demonstrated a sharp increase in the number of 
blind cases during 2008, which resulted in a sharp increase in incidence. This increase 
may be attributable to a national campaign specifically highlighting diabetic 
retinopathy among the general population, which in turn may have increased 
recording rates to the NCBI during this year. Nevertheless, in the absence of any 
other national data source, blind registries are useful for monitoring trends in 
diabetes-related blindness (237).  
Secondly, similar to previous research (14, 233, 247), we applied secondary data to 
model our annual diabetes prevalence estimates. We acknowledge that the accuracy 
of our calculations is dependent on the reliable estimation of the population with 
diagnosed diabetes. For instance, an underestimation of diabetes cases in our 
denominator would result in an increase in our attributable risk calculations. In the 
absence of a national diabetes register, annual estimates on the prevalence of 
diabetes are lacking (159). However, our model estimates are derived from four 
nationally representative studies and the increasing prevalence of diagnosed 
diabetes among the adult population in Ireland is in accordance with other countries 
(159). Therefore the diabetes prevalence estimates used in the present study are the 
best available in Ireland.  Additionally, in accordance with previous research (53, 234, 
235, 247), our denominator data does not include those with undiagnosed diabetes; 
we acknowledge that this would result in an overestimation of rates. Finally, we could 
not stratify our analysis by diabetes type and duration of disease was unknown. Our 
rates in the youngest age group serve as a proxy for those with type 1 diabetes 
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mellitus, although the small number of cases in the youngest age group could 
introduce imprecision into our estimates.  
6.5.3 Conclusions 
Despite these limitations our research provides contemporary data on the trends of 
diabetes related complications among adults aged between 18 and 69 years in 
Ireland (159). Diabetic retinopathy is potentially preventable by adequate risk factor 
control (50). Additionally, early detection and timely treatment can prevent the onset 
of sight threatening visual impairment (50, 232) . Our risk calculations indicate that 
in 2013, prevention or early detection of diabetic retinopathy may have resulted in 
82% fewer new cases of blindness in adults aged 18-49 years and 48% fewer new 
cases of blindness in adults aged 50-69 years. Although causality cannot be inferred 
in the present study, our findings highlight the need to focus on preventive measures 
for microvascular complications among people with diabetes in Ireland. 
 Evidence suggests that younger adults (149, 154, 248) and those with type 1 diabetes 
(149, 154, 248) are less likely to attend regular retinal screening examinations; non-
attendance is a risk factor for poor visual outcomes (66). Therefore, further research 
is required to explore patterns of retinal screening attendance among these groups 
in Ireland. It is essential to develop an understanding of the factors which influence 
the uptake of the national diabetic retinal screening programme in order for this new 
investment to be effective (116). Findings from this research will provide useful 
baseline statistics to monitor the future impact of the national diabetic retinal 
screening programme (122).  
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Table 11. New registrations resulting from diabetic retinopathy, estimated population data and the standardised incidence of visual impairment 
and blindness, Ireland 2004-2013. 
Year      Adult population 
Number of new cases 
due to diabetic 
retinopathy 
Incidence of visual impairment 
due to diabetic retinopathy 
(per 100,000 pop [95 % CI]) 
Incidence of blindness  
due to diabetic retinopathy 
(per 100,000 pop [95 % CI]) 
 
Total 
Diagnosed 
diabetes 
Visual 
impairment 
Blindness Total 
Diagnosed 
diabetes 
Total 
Diagnosed 
diabetes 
2004 2712428 57628 4 18 0.16 (0.05-0.3) 6.4 (2.4-13.9) 0.68 (0.4-1.0) 31.9 (21.6-45.7) 
2005 2789808 61881 6 19 0.23 (0.09-0.4) 9.6 (4.4-18.2) 0.72 (0.5-1.0) 29.9 (19.8-43.2) 
2006 2879284 65829 6 28 0.23 (0.09-0.4) 8.9 (3.9-17.6) 1.01 (0.6-1.4) 42.7 (30.5-58.1) 
2007 2990318 71893 8 25 0.26 (0.1-0.5) 11.7 (5.7-20.9) 0.87 (0.5-1.3) 35.2 (24.2-49.4) 
2008 3061169 77777 9 42 0.29 (0.1-0.5) 10.6 (5.1-19.6) 1.43 (1.0-1.9) 54.4 (40.5-71.5) 
2009 3077885 83627 5 26 0.16 (0.5-0.4) 6.4 (2.3-13.9) 0.87 (0.5-1.3) 33.1 (22.5-46.9) 
2010 3075576 89651 13 27 0.42 (0.2-0.7) 15.9 (8.9-26.4) 0.87 (0.6-1.3) 31.9 (21.6-45.7) 
2011 3077810 96470 11 29 0.35 (0.2-0.6) 12.3 (6.1-22.0) 0.94 (0.6-1.4) 30.9 (20.7-44.4) 
2012 3052159 102775 12 25 0.39 (0.2-0.7) 13.4 (6.9-23.4) 0.81(0.5-1.2) 26.7 (17.3-39.4) 
2013 3032956 109842 13 16 0.39 (0.2-0.7) 11.7 (5.7-21.0) 0.52 (0.3-0.8) 14.9 (8.2-25.1) 
120 
 
Table 12. Relative, attributable and population attributable risk of visual impairment and blindness in 
Ireland, 2013. 
 
 VI Blindness 
Relative risk (95% CI) 
No diabetes 
18-49 years 
50-69 years 
 
1 
1.7 (0.2-12.3) 
3.9 (2.0-7.4) 
 
1 
5.5 (2.2-13.6) 
1.9 (1.1-3.6) 
AR /100,000 diabetes pop 
18-49 years 
50-69 years 
 
1.0 (-0.03-7.4) 
13.4 (3.1-23.7) 
 
9.4 (0.7-19.4) 
7.8 (2.2-17.8) 
AR % in diabetes pop 
18-49 years 
50-69 years 
 
44.6 (-3.9-94.5) 
74.2 (51.0-86.4) 
 
81.6 (53.7-92.7) 
47.7 (8.4-71.9) 
PAR /100,000 pop 
18-49 years 
50-69 years 
 
0.02 (-2.2-7.3) 
0.9 (0.04-15.2) 
 
0.3 (0.01-10.3) 
0.5 (1.5-13.7) 
PAR % in total pop 
18-49 years 
50-69 years 
 
1.7 (-4.7-18.7) 
16.8 (4.5-28.7) 
 
8.5 (0.3-17.9) 
5.9 (1.8-13.1) 
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Figure 6. Age specific trends in the incidence of A) Any visual impairment; B) Mild and moderate visual impairment  and C) Blindness due to diabetic 
retinopathy among the total adult population and adults with diagnosed diabetes, Ireland 2004-2013. 
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